Data Science Funding Announcements & Notices
Data science and informatics funding announcements and notices are available from NCI and NIH programs. Browse below for opportunities, requests for information, notices, and initiatives.
| Title | FOA | Organization | Release Date | Expire Date | Purpose |
|---|---|---|---|---|---|
| Innovative Research in Cancer Nanotechnology (IRCN) (R01 Clinical Trial Not Allowed) | PAR-20-284 | NCI | This Funding Opportunity Announcement (FOA) entitled "Innovative Research in Cancer Nanotechnology (IRCN)" encourages applications promoting transformative discoveries in cancer biology and… More | ||
| Precompetitive Collaboration on Liquid Biopsy for Early Cancer Assessment: Data Management and Coordinating Unit (U24 Clinical Trial Not Allowed) | RFA-CA-23-031 | NCI | The objectives of the Early Detection Research Network (EDRN; edrn.cancer.gov) are to discover, develop and validate biomarkers and imaging methods to detect early stage cancers and to translate… More | ||
| National Cancer Institute Program Project Applications (P01 Clinical Trial Optional) | PAR-20-077 | NCI | With this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for investigator-initiated Program Project (P01) applications. The proposed Program may… More | ||
| Notice of Special Interest (NOSI): Dietary, Physical Activity, Sedentary Behavior and Sleep Assessment Methodologies Among Infants and Young Children (Birth to 5 years) through Adults | NOT-CA-21-108 | NCI | The purpose of this NOSI is to invite investigator-initiated applications addressing approaches that improve the measurement of diet, physical activity, sedentary behavior, and sleep and their… More | ||
| Notice of Special Interest (NOSI): Single-Cell Proteomics for Interrogating Premalignant and Early Malignant Lesions | NOT-CA-20-044 | NCI | Notice Special Interest NOSI): Single-Cell Proteomics Interrogating Premalignant Early Malignant Lesions Notice Number: NOT-CA-20-044 Key Dates Release Date: April 09, 2020 First Available Due Date… More | ||
| Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed) | PAR-20-131 | NCI | The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for projects to expand, improve, or transform the utility of mammalian cancer and tumor models for translational… More | ||
| Notice of Special Interest (NOSI): Advancing Cancer Data Repositories and Knowledgebases | NOT-CA-20-045 | NCI | Notice Special Interest NOSI): Advancing Cancer Data Repositories Knowledgebases Notice Number: NOT-CA-20-045 Key Dates Release Date: April 09, 2020 First Available Due Date: September 25, 2020… More | ||
| New Informatics Tools and Methods to Enhance U.S. Cancer Surveillance Research (U01 Clinical Trial Optional) | PAR-20-170 | NCI | The goal of this Funding Opportunity Announcement (FOA) is to advance surveillance science by supporting the development of new and innovative tools and methods for more efficient, detailed, timely,… More | ||
| Addressing the Primary Care Needs of Cancer Survivors (U01 Clinical Trial Required) | RFA-CA-23-025 | NCI | The purpose of this RFA is to support the development and testing of primary care practice- and health system-level interventions and strategies to promote high quality care for adult cancer… More | ||
| Cancer Adoptive Cellular Therapy Network (Can-ACT) for Adult Cancers (UG3/UH3 Clinical Trial Required) | RFA-CA-22-028 | NCI | The National Cancer Institute (NCI) intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) soliciting UG3/UH3 applications for the Cancer Adoptive Cellular Therapy… More | ||
| Cancer Adoptive Cellular Therapy Network (Can-ACT) for Pediatric Cancers (UG3/UH3 Clinical Trial Required) | RFA-CA-22-029 | NCI | The National Cancer Institute (NCI) intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) soliciting UG3/UH3 applications for the Cancer Adoptive Cellular Therapy… More | ||
| Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 Clinical Trial Optional) | RFA-CA-23-006 | NCI | The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI R01 research projects. The… More | ||
| Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed) | RFA-CA-23-002 | NCI | This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies offering novel… More | ||
| Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U54 Clinical Trials Optional) | RFA-CA-23-008 | NCI | The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI U54 Resource-Related… More | ||
| Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) | RFA-CA-23-003 | NCI | This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel… More | ||
| Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U2C Clinical Trial Optional) | RFA-CA-23-011 | NCI | The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI U2C Resource-Related Multi… More | ||
| Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) | RFA-CA-23-005 | NCI | This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the… More | ||
| Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P01 Clinical Trial Optional) | RFA-CA-23-009 | NCI | The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI P01 program projects. The… More | ||
| Revision Applications for Incorporation of Novel NCI- Supported Technology to Accelerate Cancer Research (U01 Clinical Trial Optional) | RFA-CA-23-007 | NCI | The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI U01 research projects. The… More | ||
| Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P50 Clinical Trial Optional) | RFA-CA-23-010 | NCI | The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI P50 specialized centers.… More | ||
| Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed) | RFA-CA-23-004 | NCI | This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve… More | ||
| Tobacco Control Policies to Promote Health Equity (R21 Clinical Trial Optional) | PAR-20-303 | NCI | The purpose of this Funding Opportunity Announcement (FOA) is to support observational or intervention research focused on reducing disparities in tobacco use and secondhand smoke (SHS) exposure in… More | ||
| Tobacco Control Policies to Promote Health Equity (R01 Clinical Trial Optional) | PAR-20-302 | NCI | The purpose of this Funding Opportunity Announcement (FOA) is to support observational or intervention research focused on reducing disparities in tobacco use and secondhand smoke (SHS) exposure in… More | ||
| National Cancer Institute Youth Enjoy Science Research Education Program (R25 Clinical Trial Not Allowed) | RFA-CA-21-020 | NCI | The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this National Cancer Institute (NCI) R25 program is to… More | ||
| Research to Understand and Address the Survivorship Needs of Individuals Living with Advanced Cancer (R01 Clinical Trial Optional) | RFA-CA-22-027 | NCI | The purpose of this Funding Opportunity Announcement (FOA) is to invite applications that aim to understand and address the survivorship needs of individuals living with likely incurable cancers.… More | ||
| NCI Research Specialist (Clinician Scientist) Award (R50 Clinical Trial Not Allowed) | PAR-21-306 | NCI | This Funding Opportunity Announcement (FOA) invites grant applications for the Research Specialist Award (R50) specifically for clinician scientists supporting NCI-funded clinical trials research.… More | ||
| Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed) | PAR-20-313 | NCI | Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications to support the validation of molecular/cellular/imaging markers (referred to as "… More | ||
| Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed) | PAR-20-314 | NCI | The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the adoption and validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers… More | ||
| Advancing Adolescent Tobacco Cessation Intervention Research (R34 Clinical Trial Optional) | RFA-CA-22-042 | NCI | The purpose of this RFA is to stimulate research on the development and evaluation of tobacco cessation interventions for adolescents, with an emphasis on ages 14-20. We have chosen to focus on this… More | ||
| Advancing Adolescent Tobacco Cessation Intervention Research (R01 Clinical Trial Required) | RFA-CA-22-043 | NCI | The purpose of this Funding Opportunity Announcement (FOA) is to support studies that develop, test, implement, and evaluate behavioral tobacco cessation interventions for adolescents, with a focus… More | ||
| Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01 Clinical Trial Not Allowed) | PAR-23-088 | NCI | The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the pace of translation of NCI-supported methods/assays/technologies (referred to as "assays") to the clinic.… More | ||
| Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) | RFA-CA-23-017 | NCI | The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applications for the continued development and sustainment of high-value informatics research… More | ||
| Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional) | RFA-CA-23-015 | NCI | The goal of this FOA is to advance cancer model systems that recapitulate human immunity in the tumor microenvironment to improve the predictivity of immuno-oncology studies. Proposed research… More | ||
| Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional) | RFA-CA-23-014 | NCI | The purpose of this Funding Opportunity Announcement (FOA) is to invite exploratory/developmental research grant applications (R21) for innovative informatics methods and algorithms to improve the… More | ||
| Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) | RFA-CA-23-016 | NCI | The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applications for advanced development and enhancement of emerging informatics technologies to… More | ||
| Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research (R21 Clinical Trial Not Allowed) | PAR-21-061 | NCI | This Funding Opportunity Announcement (FOA) represents the continuation of an NCI program to enhance the diversity of the pool of the cancer research workforce by recruiting and supporting eligible… More | ||
| Basic/Translational Research on Health Disparities in Underrepresented People Living with HIV (PLWH) and Cancer (R21 Clinical Trial Not Allowed) | RFA-CA-22-057 | NCI | Through this funding opportunity announcement, the National Cancer Institute (NCI) intends to focus on the biological interactions of cancer health disparities in people living with HIV (PLWH) from… More | ||
| The role of Epstein Barr virus (EBV) infection in Non-Hodgkin Lymphoma (NHL) and Hodgkin disease (HD) development with or without an underlying HIV infection (U01 Clinical Trial Optional) | PAR-21-348 | NCI | The role of EBV infection on Non-Hodgkin Lymphoma (NHL) and Hodgkin disease (HD) development with or without an underlying HIV infection and AIDS will increase our understanding through mechanistic,… More | ||
| Basic/Translational Research on Health Disparities in Underrepresented People Living with HIV (PLWH) and Cancer (R01 Clinical Trial Not Allowed) | RFA-CA-22-056 | NCI | Through this funding opportunity announcement, the National Cancer Institute (NCI) intends to focus on the biological interactions of cancer health disparities in people living with HIV (PLWH) from… More | ||
| Cancer Research Education Grants Program - Curriculum or Methods Development (R25 Clinical Trial Not Allowed) | PAR-21-065 | NCI | The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NCI R25 program is to support educational activities… More | ||
| Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2021, 2022, and 2023 (P50 Clinical Trial Required) | PAR-20-305 | NCI | Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) invites applications for P50 Research Center Grants for Specialized Programs of Research Excellence (SPORE).… More | ||
| Notice of Special Interest (NOSI): Leveraging Real-World Imaging Data for Artificial Intelligence-based Modeling and Early Detection of Abdominal Cancers | NOT-CA-21-028 | NCI | The purpose of this Notice of Special Interest (NOSI) is to solicit applications to support the secondary use of real-world data for Artificial Intelligence (AI)-based predictive modeling with the… More | ||
| National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required) | PAR-21-033 | NCI | The purpose of this Funding Opportunity Announcement (FOA) is to seek research projects that implement early phase (Phase 0, I, and II) investigator-initiated clinical trials focused on cancer-… More | ||
| Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed) | PAR-21-166 | NCI | The purpose of this Funding Opportunity Announcement (FOA) is to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in… More | ||
| Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required) | PAR-21-035 | NCI | Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for support of investigator-initiated clinical trials that have the potential to reduce… More | ||
| NCI Cancer Moonshot Scholars Diversity Program (CMSDP) (R01 Clinical Trial Optional) | RFA-CA-22-050 | NCI | This Funding Opportunity Announcement (FOA) supports the Cancer Moonshot Scholars Diversity Program (CMSDP) and solicits R01 grant applications that propose independent research projects within the… More | ||
| Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional) | PAR-21-190 | NCI | This funding opportunity announcement (FOA) encourages applications for research in cancer control and population sciences. The overarching goal is to provide support to promote research efforts on… More | ||
| Notice of Special Interest (NOSI): Validation of Digital Health and Artificial Intelligence Tools for Improved Assessment in Epidemiological, Clinical, and Intervention Research | NOT-CA-22-037 | NCI | The purpose of this Notice of Special Interest (NOSI) is to encourage grant applications to support the evaluation of the utility and validity of digital health and artificial intelligence (AI) tools… More | ||
| The NCI Transition Career Development Award (K22 Independent Basic Experimental Studies with Humans Required) | PAR-21-318 | NCI | This Funding Opportunity Announcement (FOA) represents the continuation of an NCI program to facilitate the transition of investigators in mentored, non-independent cancer research positions to… More | ||
| The NCI Transition Career Development Award (K22 - Independent Clinical Trial Required) | PAR-21-111 | NCI | This Funding Opportunity Announcement (FOA) represents the continuation of an NCI program to facilitate the transition of investigators in mentored, non-independent cancer research positions to… More | ||
| The NCI Transition Career Development Award (K22 - Independent Clinical Trial Not Allowed) | PAR-21-128 | NCI | This Funding Opportunity Announcement (FOA) represents the continuation of an NCI program to facilitate the transition of investigators in mentored, non-independent cancer research positions to… More | ||
| Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional) | PAR-21-206 | NCI | The purpose of this Funding Opportunity Announcement (FOA) is to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in… More | ||
| Pancreatic Cancer Detection Consortium: Management and Data Coordination Unit (U24 Clinical Trial Not Allowed) | PAR-21-335 | NCI | The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for the Research Units (RUs), one of the two scientific components of the Pancreatic Cancer Detection Consortium… More | ||
| Pancreatic Cancer Detection Consortium: Research Units (U01 Clinical Trial Optional) | PAR-21-334 | NCI | The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for the Research Units (RUs), one of the two scientific components of the Pancreatic Cancer Detection Consortium… More | ||
| NCI Transition Career Development Award to Promote Diversity (K22 Independent Clinical Trial Not Allowed) | PAR-21-301 | NCI | The purpose of the NCI Transition Career Development Award to Promote Diversity (K22) is to assist postdoctoral fellows or individuals in equivalent positions to transition to positions of assistant… More | ||
| Basic Research in Cancer Health Disparities (R03 Clinical Trial Not Allowed) | PAR-21-324 | NCI | This Funding Opportunity Announcement (FOA) encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health… More | ||
| Mechanisms that Impact Cancer Risk after Bariatric Surgery (R21 Clinical Trial Not Allowed) | PAR-21-332 | NCI | Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for support of investigator-initiated studies addressing mechanisms by which bariatric… More | ||
| NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity (K08 Clinical Trial Required) | PAR-21-299 | NCI | The purpose of the NCI Mentored Clinical Scientist Career Development Award (K08) program is to prepare individuals for careers that have a significant impact on the health-related research needs of… More | ||
| Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed) | PAR-21-322 | NCI | This Funding Opportunity Announcement (FOA) encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health… More | ||
| Cancer Research Education Grants Program - Courses for Skills Development (R25 Clinical Trial Not Allowed) | PAR-21-278 | NCI | The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NCI R25 program is to support educational activities… More | ||
| NCI Transition Career Development Award to Promote Diversity (K22 Clinical Trial Required) | PAR-21-302 | NCI | The purpose of the NCI Transition Career Development Award to Promote Diversity is to assist postdoctoral fellows or individuals in equivalent positions to transition to positions of assistant… More | ||
| Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed) | PAR-21-294 | NCI | The purpose of this Funding Opportunity Announcement (FOA) is to invite research grant applications (R01) for the development and use of current and emerging molecular imaging methods to gain… More | ||
| Mechanisms that Impact Cancer Risk after Bariatric Surgery (R01 Clinical Trial Optional) | PAR-21-331 | NCI | Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for support of investigator-initiated studies addressing mechanisms by which bariatric… More | ||
| NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity (K08 Independent Clinical Trial Not Allowed) | PAR-21-300 | NCI | The purpose of the NCI Mentored Clinical Scientist Career Development Award (K08) program is to prepare individuals for careers that have a significant impact on the health-related research needs of… More | ||
| Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed) | PAR-21-323 | NCI | This Funding Opportunity Announcement (FOA) encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health… More | ||
| Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional) | PAR-21-290 | NCI | Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) seeks research project (R01) grant applications describing projects that integrate imaging and fluid-based… More | ||
| Cancer Research Education Grants Program - Research Experiences (R25 Clinical Trial Not Allowed) | PAR-21-279 | NCI | The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NCI R25 program is to support educational activities… More | ||
| Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed) | PAR-22-049 | NCI | This Funding Opportunity Announcement (FOA) will support extramural research to investigate and mitigate challenges facing clinical assay development and subsequent analytical validation due to… More | ||
| Exploratory Grants in Cancer Control (R21 Clinical Trial Optional) | PAR-21-341 | NCI | This funding opportunity announcement (FOA) encourages the submission of exploratory/developmental research grant (R21) applications that focus on different aspects of cancer control by modifying… More | ||
| Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed) | PAR-21-330 | NCI | This Funding Opportunity Announcement (FOA) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of… More | ||
| Research Projects in Physical Sciences-Oncology (U01 Clinical Trial Optional) | PAR-22-147 | NCI | Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites U01 cooperative agreement applications for Physical Sciences-Oncology Network (PS-ON). The goal of the… More | ||
| Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional) | PAR-21-329 | NCI | The purpose of this Funding Opportunity Announcement (FOA) is to support collaborative research projects designed to address adverse sequelae of cancer therapies that persist and become chronic… More | ||
| NCI Outstanding Investigator Award (R35 Clinical Trial Optional) | RFA-CA-22-045 | NCI | This Funding Opportunity Announcement (FOA) invites grant applications for the Outstanding Investigator Award (R35) in any area of cancer research.The objective of the National Cancer Institute (NCI… More | ||
| NCI Mentored Research Scientist Development Award to Promote Diversity (K01 Clinical Trial Required) | PAR-21-296 | NCI | This Funding Opportunity Announcement (FOA) is a continuation of the NCI Mentored Research Scientist Development Award to Promote Diversity (K01) to enhance the diversity of thought in the NCI-funded… More | ||
| NCI Mentored Research Scientist Development Award to Promote Diversity (K01 Independent Clinical Trial Not Allowed) | PAR-21-295 | NCI | This Funding Opportunity Announcement (FOA) is a continuation of the NCI Mentored Research Scientist Development Award to Promote Diversity (K01) to enhance the diversity of thought in the NCI-funded… More | ||
| Toward Translation of Nanotechnology Cancer Interventions (TTNCI) (R01 Clinical Trial Not Allowed) | PAR-22-071 | NCI | This Funding Opportunity Announcement (FOA), entitled "Toward Translation of Nanotechnology Cancer Interventions" (TTNCI), encourages applications for advanced pre-clinical research,… More | ||
| Method to Extend Research in Time (MERIT) Award Extension Request (Type 4 Clinical Trial Optional) | PAR-21-138 | NCI | The National Cancer Institute (NCI) Method to Extend Research in Time (MERIT) (R37) Award provides extended grant support to Early Stage Investigators (ESIs). By providing such an opportunity for… More | ||
| Notice of Special Interest (NOSI): Technologies and Informatics Tools for Cancer Metabolomics | NOT-CA-22-083 | NCI | This Notice of Special Interest (NOSI) is to alert the community that the National Cancer Institute (NCI) is seeking to support development of innovative technologies and informatics tools for… More | ||
| Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30 Clinical Trial Optional) | PAR-21-321 | NCI | This Funding Opportunity Announcement (FOA) invites applications for P30 Cancer Center Support Grants (CCSGs) to support NCI-designated Cancer Centers. CCSGs support three types of Cancer Centers: 1… More | ||
| Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed) | PAR-22-090 | NCI | The purpose of this engineering-oriented funding opportunity announcement (FOA) is to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to… More | ||
| Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer (R21 Clinical Trial Not Allowed) | PAR-22-062 | NCI | The purpose of this Funding Opportunity Announcement (FOA) is to support exploratory/development basic research projects that elucidate mechanisms by which the human microbiome inhibit or enhance… More | ||
| Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional) | PAR-22-091 | NCI | The purpose of this engineering-oriented funding opportunity announcement (FOA) is to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to… More | ||
| Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer (R01 Clinical Trial Not Allowed) | PAR-22-061 | NCI | The purpose of this Funding Opportunity Announcement (FOA) is to support basic research that elucidates mechanisms by which the human microbiome inhibit or enhance anti-tumor immune responses, and to… More | ||
| Research Opportunities in Established Cancer Epidemiology Cohort Studies (U01 Clinical Trial Not Allowed) | PAR-22-162 | NCI | Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) encourages grant applications to support cancer epidemiology research in established cohort studies, defined… More | ||
| Cancer Epidemiology Cohorts: Building the Next Generation of Research Cohorts (U01 Clinical Trial Not Allowed) | PAR-22-161 | NCI | Through this funding opportunity announcement, the National Cancer Institute (NCI) solicits applications to Cancer Epidemiology Cohorts: Building the Next Generation of Research Cohorts PAR. This… More | ||
| Dissemination and Implementation Research in Health (R01 Clinical Trial Optional) | PAR-22-105 | NCI | The purpose of this Funding Opportunity Announcement (FOA) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration,… More | ||
| Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01 Clinical Trial Optional) | PAR-22-099 | NCI | This Funding Opportunity Announcement (FOA) will support the development and characterization of state-of-the-art biomimetic tissue-engineered technologies for cancer research. Collaborative,… More | ||
| Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R21 Clinical Trial Not Allowed) | PAR-22-086 | NCI | This Funding Opportunity Announcement (FOA) solicits grant applications proposing to utilize bacteria, archaebacteria, bacteriophages, or other non-oncolytic viruses and their natural products to… More | ||
| Dissemination and Implementation Research in Health (R21 Clinical Trial Optional) | PAR-22-109 | NCI | The purpose of this Funding Opportunity Announcement (FOA) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration,… More | ||
| Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R01 Clinical Trial Not Allowed) | PAR-22-139 | NCI | The purpose of this Funding Opportunity Announcement (FOA) is to solicit R01 research projects utilizing state-of-the-art cancer biology methods and model systems to study effects of different types… More | ||
| Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R01 Clinical Trial Not Allowed) | PAR-22-083 | NCI | The purpose of this Funding Opportunity Announcement (FOA) is to promote epidemiologic research investigating novel and innovative hypotheses on emerging risk factors (biological, environmental, and… More | ||
| Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R01 Clinical Trial Not Allowed) | PAR-22-085 | NCI | This Funding Opportunity Announcement (FOA) solicits grant applications proposing to utilize bacteria, archaebacteria, bacteriophages, or other non-oncolytic viruses and their natural products to… More | ||
| Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R21 Clinical Trial Not Allowed) | PAR-22-140 | NCI | The STRIPE program seeks to support pre-clinical research projects utilizing state-of-the-art cancer biology methods and model systems that study how radiopharmaceutical therapy (RPT) agents affect… More | ||
| Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R21 Clinical Trial Not Allowed) | PAR-22-084 | NCI | The purpose of this Funding Opportunity Announcement (FOA) is to promote epidemiologic research investigating novel and innovative hypotheses on emerging risk factors (biological, environmental, and… More | ||
| Discovery and Development of Natural Products for Cancer Interception and Prevention (UG3/UH3 Clinical Trial Not Allowed) | RFA-CA-23-028 | NCI | The overall goal of this UG3/UH3 Exploratory/Developmental phased initiative is to support the discovery and development of novel natural products that are safe, nontoxic, and efficacious for cancer… More | ||
| The Metastasis Research Network (MetNet): MetNet Research Projects (U01 Clinical Trial Not Allowed) | PAR-22-234 | NCI | The MetNet is a collection of Research Centers that support using systems level approaches to understand the non-linear, dynamic and emergent processes in metastasis. Considering chronological… More | ||
| NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional) | PAR-22-216 | NCI | This Funding Opportunity Announcement (FOA) supports the development of new exploratory research in cancer diagnosis, treatment, imaging, symptom/toxicity, and prevention clinical trials; correlative… More | ||
| Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional) | PAR-22-174 | NCI | The purpose of this FOA is to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors,… More | ||
| Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed) | PAR-22-106 | NCI | The purpose of this Funding Opportunity Announcement (FOA) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration,… More | ||
| Biology of Bladder Cancer (R21 Clinical Trial Optional) | PAR-22-219 | NCI | This Funding Opportunity Announcement (FOA) solicits applications investigating the biology and underlying mechanisms of bladder cancer. Bladder cancer is a significant health problem both in the… More | ||
| Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional) | PAR-22-243 | NCI | The purpose of this funding opportunity announcement is to encourage collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution… More | ||
| Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R01 Clinical Trial Optional) | PAR-22-164 | NCI | Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) announces its interest in supporting meritorious research projects in three distinct domains related to cancer… More | ||
| Precision Approaches in Radiation Synthetic Combinations (PAIRS, R01 Clinical Trial Optional) | PAR-22-198 | NCI | The purpose of this Funding Opportunity Announcement (FOA) is to solicit R01 research projects that investigate actionable synthetic vulnerabilities that can be conditionally paired with tumor… More | ||
| Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional) | PAR-22-173 | NCI | The purpose of this FOA is to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors,… More | ||
| Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Cancer and Precancerous Lesions Associated with Lethal Phenotypes (R01 Clinical Trial Optional) | PAR-22-131 | NCI | This Funding Opportunity Announcement (FOA) will support the development of state-of-the-art projects that integrate imaging, biomarkers, digital pathomics, glycomics, metabolomics, other omic… More | ||
| Bioengineering Research Grants (BRG) (R01 Clinical Trial Not Allowed) | PAR-22-242 | NCI | The purpose of this funding opportunity announcement is to encourage collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution… More | ||
| Precision Approaches in Radiation Synthetic Combinations (PAIRS, R21 Clinical Trial Optional) | PAR-22-199 | NCI | Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) will solicit R01 research projects that seek to investigate actionable synthetic vulnerabilities that can be… More | ||
| Biology of Bladder Cancer (R01 Clinical Trial Optional) | PAR-22-218 | NCI | This Funding Opportunity Announcement (FOA) solicits applications investigating the biology and underlying mechanisms of bladder cancer. Bladder cancer is a significant health problem both in the… More | ||
| Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R21 Clinical Trial Optional) | PAR-22-165 | NCI | Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) announces its interest in supporting meritorious research projects in three distinct domains related to cancer… More | ||
| Mechanistic links between diet, lipid metabolism, and tumor growth and progression (U01 Clinical Trial Not Allowed) | PAR-23-051 | NCI | The purpose of this funding opportunity announcement is to request applications that propose mechanistic investigations of the links between diet, lipid metabolism and tumor growth and progression.… More | ||
| Mechanistic links between diet, lipid metabolism, and tumor growth and progression (UH2 Clinical Trial Not Allowed) | PAR-23-052 | NCI | The purpose of this funding opportunity announcement is to request applications that propose mechanistic investigations of the links between diet, lipid metabolism and tumor growth and progression.… More | ||
| Co-infection and Cancer (R01 Clinical Trial Not Allowed) | PAR-23-055 | NCI | This initiative seeks to enhance our mechanistic and epidemiologic understanding of infection-related cancers, with a focus on the etiologic roles of co-infection in cancer. Preference will be… More |
||
| Co-infection and Cancer (R21 Clinical Trial Not Allowed) | PAR-23-056 | NCI | The purpose of this Funding Opportunity Announcement (FOA) is to enhance mechanistic and epidemiologic investigations addressing the roles of co-infection and cancer to shed light on presently… More | ||
| Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required) | PAR-22-256 | NCI | Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) intends to accelerate the development of evidence-based cancer-related interventions to improve health equity… More | ||
| NCI Small Grants Program for Cancer Research for Years 2023, 2024, and 2025 (NCI Omnibus) (R03 Clinical Trial Optional) | PAR-23-058 | NCI | This funding opportunity announcement (FOA) supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports… More | ||
| National Cancer Institute Program Project Applications for the Years 2023, 2024, and 2025 (P01 Clinical Trial Optional) | PAR-23-059 | NCI | Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for investigator-initiated Program Project (P01) applications. The proposed Program may… More | ||
| Global Infectious Disease Research Training Program (D43 Clinical Trial Optional) | PAR-21-120 | FIC | This Funding Opportunity Announcement (FOA) encourages joint applications for the Global Infectious Disease (GID) Research Training programs from U.S. and low- and middle-income country (LMIC)… More | ||
| Emerging Global Leader Award (K43 Independent Clinical Trial Required) | PAR-21-251 | FIC | This is a reissue of the Emerging Global Leader Program (K43) to align with the clinical trials policy. | ||
| Emerging Global Leader Award (K43 Independent Clinical Trial Not Allowed) | PAR-21-252 | FIC | This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study… More | ||
| International Research Ethics Education and Curriculum Development Award (R25 Clinical Trial Not Allowed) | PAR-22-118 | FIC | Education programs supported by this initiative will equip scientists, health professionals and academics in low and middle-income countries with in-depth knowledge of the ethical principles,… More | ||
| Chronic, Non-Communicable Diseases and Disorders Across the Lifespan: Fogarty International Research Training Award (NCD-LIFESPAN) (D43 Clinical Trial Optional) | PAR-22-104 | FIC | This funding opportunity announcement (FOA) is a reissue due to an omission of TRAINING RECORD review questions in Section V. This FOA encourages applications for the Chronic, Non-Communicable… More | ||
| Infrastructure Development Training Programs for Critical HIV Research at Low-and Middle-Income Country Institutions (G11 Clinical Trials Not Allowed) | PAR-22-153 | FIC | The overall goal of the Fogarty International Center (FIC) HIV Research Training Program is to strengthen the scientific capacity of institutions in low- and middle-income countries (LMICs) to… More | ||
| Fogarty HIV Research Training Program for Low-and Middle-Income Country Institutions (D43 Clinical Trial Optional) | PAR-22-151 | FIC | The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications for research training programs to strengthen the scientific capacity of institutions in low- and middle-income… More | ||
| Global Brain and Nervous System Disorders Research Across the Lifespan (R21 Clinical Trial Optional) | PAR-22-098 | FIC | This is a reissue to correct a few errors and omissions. This Funding Opportunity Announcement (FOA) encourages exploratory/developmental research grant applications, proposing the development of… More | ||
| Global Brain and Nervous System Disorders Research Across the Lifespan (R01 Clinical Trials Optional) | PAR-22-097 | FIC | This is a reissue to correct errors and omissions. This Funding Opportunity Announcement (FOA) encourages grant applications for the conduct of innovative, collaborative research projects between U.S… More | ||
| Translational Centers for Microphysiological Systems (TraCe MPS) (U2C Clinical Trials Not Allowed) | RFA-TR-23-001 | NCATS | The purpose of this funding opportunity announcement (FOA) is to establish Centers to support research that will accelerate the translational use of Microphysiological Systems (MPS) in drug… More | ||
| Emergency Awards: HEAL Initiative: Translational Science Career Enhancement Awards for Early and Mid-career Investigators (K18 Clinical Trials Not Allowed) | PAR-22-058 | NCATS | NCATS is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS. Please see Determination that a Public Health Emergency Exists Nationwide as the Result of… More | ||
| Emergency Awards: HEAL Initiative- New Innovator Award (DP2 Clinical Trial Not Allowed) | RFA-TR-22-013 | NCATS | NCATS is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS. Please see Determination that a Public Health Emergency Exists Nationwide as the Result of… More | ||
| Emergency Awards: HEAL Initiative-Early-Stage Discovery of New Pain and Opioid Use Disorder Targets Within the Understudied Druggable Proteome (R21 Clinical Trial Not Allowed) | RFA-TR-22-011 | NCATS | NCATS is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS. Please see Determination that a Public Health Emergency Exists Nationwide as the Result of… More | ||
| Drug Development Collaboratory (UG3/UH3 Clinical Trial Required) | PAR-20-301 | NCATS | The purpose of this Funding Opportunity Announcement (FOA) is to support intramural-extramural collaborations on late-stage translational science projects between NCATS Therapeutic Development Branch… More | ||
| Basket Clinical Trials of Drugs Targeting Shared Molecular Etiologies in Multiple Rare Diseases (U44 Clinical Trial Required) | RFA-TR-22-029 | NCATS | The purpose of this Funding Opportunity Announcement (FOA) is to support basket clinical trials of drugs targeting shared molecular etiologies in more than one rare disease. To facilitate clinical… More | ||
| Botulinum Toxin Potency Assay using Tissue Chips (BoT PATCh) (U43/U44 - Clinical Trail Not Allowed) | RFA-TR-22-032 | NCATS | This FOA provides support using the SBIR cooperative agreement mechanisms for the development, regulatory qualification and commercialization of alternative approaches methods (NAMs) that… More | ||
| Botulinum Toxin Potency Assay using Tissue Chips (BoT PATCh) (UT1, UT2 Clinical Trail Not Allowed) | RFA-TR-22-031 | NCATS | This FOA provides support using the STTR cooperative agreement mechanisms for the development, regulatory qualification and commercialization of alternative approaches methods (NAMs) that… More | ||
| Limited Competition: Small Grant Program for the NCATS Clinical and Translational Science Award (CTSA) Program (R03 Clinical Trial Optional) | PAR-21-121 | NCATS | The purpose of this FOA is to enhance the capability of NCATS CTSA Program KL2 scholars and recipients of diversity and re-entry supplements supported by the CTSA Program to conduct research as they… More | ||
| Pilot Projects Investigating Understudied Proteins Associated with Rare Diseases (R03 Clinical Trial Not Allowed) | RFA-TR-22-030 | NCATS | The purpose of this funding opportunity announcement (FOA) is to solicit applications for pilot projects to elucidate a role for understudied proteins associated with rare diseases. Awards will… More | ||
| Limited Competition: High Impact Specialized Innovation Programs in Clinical and Translational Science for UM1 CTSA Hub Awards (RC2 Clinical Trials Not Allowed) | PAR-21-340 | NCATS | The purpose of the High Impact Specialized Innovation Programs (SIPs) is to support the development and demonstration of unique hub capabilities, research platforms and/or resources to address in a… More | ||
| Limited Competition: Ruth L. Kirschstein National Research Service Award (NRSA) Predoctoral Research Training Grant for the Clinical and Translational Science Awards (CTSA) Program (T32 Clinical Trial Not Allowed) | PAR-21-337 | NCATS | The National Center for Advancing Translational Sciences (NCATS) will award Ruth L. Kirschstein National Research Service Award (NRSA) Predoctoral Institutional Research Training Grants for the… More | ||
| Clinical and Translational Science Award (UM1 Clinical Trial Optional) | PAR-21-293 | NCATS | This funding opportunity announcement (FOA) invites applications for the Clinical and Translational Science Award (CTSA) Program hubs that will be part of a national, collaborative consortium focused… More | ||
| Limited Competition: Mentored Research Career Development Program Award in Clinical and Translational Science Awards (CTSA) Program (K12 Clinical Trial Optional) | PAR-21-336 | NCATS | The National Center for Advancing Translational Sciences (NCATS) will award Institutional Research Career Development (K12) programs through the Clinical and Translational Science Awards (CTSA). | ||
| Limited Competition: NCATS Clinical and Translational Science Award (CTSA) Program Research Education Grants Programs (R25 - Clinical Trial Not Allowed) | PAR-21-339 | NCATS | The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that… More | ||
| Limited Competition: Ruth L. Kirschstein National Research Service Award (NRSA) Postdoctoral Research Training Grant for the Clinical and Translational Science Awards (CTSA) Program (T32 Clinical Trial Not Allowed) | PAR-21-338 | NCATS | The National Center for Advancing Translational Sciences (NCATS) will award Ruth L. Kirschstein National Research Service Award (NRSA) Postdoctoral Institutional Research Training Grants for the… More | ||
| Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed) | PAR-22-101 | NCATS | This Funding Opportunity Announcement (FOA) invites researchers to submit applications for support of clinical projects that address critical needs for clinical trial readiness in rare diseases. The… More | ||
| Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R03 Clinical Trial Not Allowed) | PAR-22-100 | NCATS | This Funding Opportunity Announcement (FOA) invites researchers to submit applications for support of clinical projects that address critical needs for clinical trial readiness in rare diseases. The… More | ||
| Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional) | PAR-22-167 | NCATS | The Clinical and Translational Science Award (CTSA) Program Collaborative and Innovative Acceleration Award (CCIA) supports synergistic activities that accelerate the translational research process… More | ||
| Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Natural Products (Collaborative UG3/UH3 Clinical Trial Required) | PAR-20-215 | NCCIH | This Funding Opportunity Announcement (FOA) encourages cooperative agreement applications for investigator-initiated, multi-site, clinical trials (Phase III and beyond) to study the effects of… More | ||
| Natural Product Multi-Site Clinical Trial Data Coordinating Center (Collaborative U24 Clinical Trial Required) | PAR-20-219 | NCCIH | This Funding Opportunity Announcement (FOA), utilizing the U24 grant funding mechanism, encourages applications for a collaborating Data Coordinating Center (DCC) application that accompanies an… More | ||
| NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required) | PAR-20-218 | NCCIH | This Funding Opportunity Announcement (FOA) encourages applications for investigator-initiated, early phase, clinical trials of natural products (i.e., botanicals, dietary supplements, and probiotics… More | ||
| Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required) | PAR-20-154 | NCCIH | This Funding Opportunity Announcement (FOA) encourages applications for investigator-initiated fully remotely delivered and conducted clinical trials to assess the efficacy or effectiveness of… More | ||
| NCCIH Natural Product Mid Phase Clinical Trial Cooperative Agreement (U01 Clinical Trial Required) | PAR-20-216 | NCCIH | This Funding Opportunity Announcement (FOA) invites cooperative agreement applications for investigator-initiated mid-phase clinical trials of natural products. All applications submitted under this… More | ||
| Center of Excellence for Research on Complementary and Integrative Health (P01,Clinical Trial Optional) | PAR-20-138 | NCCIH | This Funding Opportunity Announcement (FOA) encourages the submission of applications requiring multi-project, synergistic collaborations blending multiple research approaches from outstanding… More | ||
| NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required) | PAR-20-217 | NCCIH | This Funding Opportunity Announcement (FOA) encourages applications for investigator-initiated, early phase, clinical trials of natural products (i.e., botanicals, dietary supplements, and probiotics… More | ||
| Promoting Research on Music and Health: Phased Innovation Award for Music Interventions (R61/R33 Clinical Trial Optional) | PAR-20-266 | NCCIH | The purpose of this Funding Opportunity Announcement (FOA) is to promote innovative research on music and health with an emphasis on developing music interventions aimed at understanding their… More | ||
| Notice of Special Interest (NOSI): Methods Development in Natural Products Research (SBIR/STTR) | NOT-AT-20-015 | NCCIH | Notice Special Interest NOSI): Methods Development Natural Products Research SBIR/STTR) Notice Number: NOT-AT-20-015 Key Dates Release Date: July 16, 202 First Available Due Date: September 05, 2020… More | ||
| Limited Competition for the Continuation or Revision of Multisite Clinical Trial Clinical Coordinating Center (Collaborative UH3 Clinical Trial Optional) | PAR-21-117 | NCCIH | This Funding Opportunity Announcement (FOA) encourages applications for competing renewal of Clinical Coordinating Center (CCC) for ongoing clinical trials supported by NCCIH; or competitive… More | ||
| Limited Competition for the Continuation of Multisite Clinical Trial Data Coordinating Center (Collaborative U24 Clinical Trial Optional) | PAR-21-116 | NCCIH | This Funding Opportunity Announcement (FOA), utilizing the U24 grant funding mechanism, encourages applications for competing renewal of Data Coordinating Center (DCC) for ongoing clinical trials… More | ||
| Research Network to Promote Multidisciplinary Mechanistic and Translational Studies of Sickle Cell Disease Pain (U24, Clinical Trial Optional) | RFA-AT-24-001 | NCCIH | The purpose of this FOA is to support a Research Network that promotes multidisciplinary mechanistic and translational studies of Sickle Cell Disease (SCD) pain. This network is expected to develop… More | ||
| Notice of Special Interest: NCCIH Administrative Supplements to NCATS CTSA Programs for Scholars Pursuing Complementary Health Research Career Development | NOT-AT-20-010 | NCCIH | Notice Special Interest: NCCIH Administrative Supplements NCATS CTSA Programs Scholars Pursuing Complementary Health Research Career Development Notice Number: NOT-AT-20-010 Key Dates Release Date:… More | ||
| NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required) | PAR-21-241 | NCCIH | This Funding Opportunity Announcement (FOA) invites applications for investigator-initiated clinical trials of complementary and integrative health approaches with physical and/or psychological… More | ||
| Data Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Mind and Body Interventions (Collaborative U24 Clinical Trial Required) | PAR-21-242 | NCCIH | This Funding Opportunity Announcement (FOA), utilizing the U24 grant funding mechanism, encourages applications for a collaborating Data Coordinating Center (DCC) application that accompanies an… More | ||
| Feasibility Clinical Trials of Mind and Body Interventions for NCCIH High Priority Research Topics (R34 Clinical Trial Required) | PAR-21-240 | NCCIH | The goal of this funding opportunity is to support early phase clinical trials of complementary and integrative health approaches with physical and/or psychological therapeutic inputs (often called… More | ||
| Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Mind and Body Interventions (Collaborative UG3/UH3 Clinical Trial Required) | PAR-21-243 | NCCIH | This Funding Opportunity Announcement (FOA) encourages applications for investigator-initiated multi-site clinical trials (e.g. efficacy, effectiveness or pragmatic trials) to study the effects of… More | ||
| Notice of Special Interest (NOSI): Promoting Research on Interoception and Its Impact on Health and Disease | NOT-AT-21-002 | NCCIH | The purpose of this NOSI is to promote innovative and rigorous research on interoception and its impact on health and disease. This initiative is broadly supported by many participating NIH… More | ||
| NEI Collaborative Clinical Vision Research : Chair's Grant (UG1-Clinical Trial Required) | PAR-21-041 | NEI | The NEI uses UG1 cooperative agreement awards to support investigator-initiated large-scale clinical trials, human gene-transfer and stem cell therapy trials, and other complex or high resource- or… More | ||
| NEI Collaborative Clinical Vision Project: Resource Center Grant (UG1- Clinical Trial Required) | PAR-21-043 | NEI | The NEI uses UG1 cooperative agreement awards to support investigator-initiated large-scale clinical trials, human gene-transfer and stem cell therapy trials, and other complex or high resource- or… More | ||
| NEI Collaborative Clinical Vision Research Project: Coordinating Center Grant (UG1 Clinical Trial Required) | PAR-21-042 | NEI | The NEI uses UG1 cooperative agreement awards to support investigator-initiated large-scale clinical trials, human gene-transfer and stem cell therapy trials, and other complex or high resource- or… More | ||
| NEI Institutional Mentored Physician Scientist Award (K12 Clinical Trial Optional) | PAR-21-073 | NEI | The purpose of this Funding Opportunity Announcement (FOA) is to encourage institutions to propose creative and innovative institutional research career development programs which prepare clinically-… More | ||
| BRAIN Initiative: New Concepts and Early-Stage Research for Recording and Modulation in the Nervous System (R21) (Clinical Trial Not Allowed) | RFA-EY-21-001 | NEI | A central goal of the BRAIN Initiative is to understand how electrical and chemical signals code information in neural circuits and give rise to sensations, thoughts, emotions and actions. While… More | ||
| India Collaborative Vision Research Program (R01 Clinical Trial Not Allowed) | PAR-21-249 | NEI | This funding Opportunity Announcement (FOA) encourages Multiple Principal Investigator (Multi-PD/PI) applications from United States (U.S.) and Indian institution as bilateral collaborations that… More | ||
| BRAIN Initiative-Related Research Education: Short Courses (R25 Clinical Trial Not Allowed) | RFA-EY-21-003 | NEI | The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this Brain Research through Advancing Innovative… More | ||
| NEI Vision Research Epidemiology Grant (UG1 Clinical Trial Not Allowed) | PAR-21-204 | NEI | The National Eye Institute (NEI) supports investigator-initiated, complex, multi-center and other high resource risk epidemiologic studies under the cooperative agreement mechanism, UG1 activity code… More | ||
| NEI Cooperative Agreement for Early-Stage Clinical Trials with Greater than Minimal Risk (U01 Clinical Trial Required) | PAR-22-149 | NEI | The NEI uses U01 cooperative agreement awards to support investigator-initiated early-stage clinical trials that are greater than minimal risk and typically are Phase I or II trials. The risk level… More | ||
| NEI Research Grant for Vision-Related Secondary Data Analysis (R21 Clinical Trial Not Allowed) | PAR-22-141 | NEI | The goal of this funding opportunity announcement (FOA) is to fund meritorious vision-related research projects that involve secondary data analyses using existing database resources. The development… More | ||
| NEI Regenerative Medicine Clinical Trial Planning Grant (R34 - Clinical Trials Not Allowed) | PAR-22-135 | NEI | The National Eye Institute (NEI) Audacious Goal Initiative (AGI) is an effort to push the boundaries of vision science and restore vision through regeneration of cells in the retina. AGI research… More | ||
| NEI Clinical Research Study Planning Grant Program (R34 Clinical Trial Not Allowed) | PAR-22-128 | NEI | The National Eye Institute (NEI) supports large-scale clinical vision research projects, including randomized clinical trials and epidemiologic studies. At the time of submission, applications… More | ||
| Notice of Special Interest (NOSI): Clarification of the Objectives and Program Elements in NHGRI Applications Submitted in Response to the "Ruth L. Kirschstein NRSA Institutional Research Training Grants (Parent T32)" | NOT-HG-21-032 | NHGRI | The National Human Genome Research Institute (NHGRI) is issuing this Notice to highlight interest in receiving grant applications focused in the following area(s): 1.Genome sciences to support… More |
||
| Notice of Special Interest: Genomic Data Repositories (PAR-20-089) and Knowledgebases (PAR-20-097) | NOT-HG-20-017 | NHGRI | Notice Special Interest: Genomic Data Repositories PAR-20-089) Knowledgebases PAR-20-097) Notice Number: NOT-HG-20-017 Key Dates Release Date: February 6, 2020 First Available Due Date: 25, 2020… More | ||
| Mentored Research Experiences for Genetic Counselors (R25) | PAR-21-074 | NHGRI | The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this NHGRI R25 program is to support educational activities… More | ||
| Research Experiences in Genomic Research for Data Scientists (R25) | PAR-21-075 | NHGRI | The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this NHGRI R25 program is to support research experiences in… More | ||
| Genomic Community Resources (U24 Clinical Trial Not Allowed) | PAR-20-100 | NHGRI | To facilitate genomic research and the dissemination of its products, NHGRI supports genomic resources that are crucial for basic research, disease studies, model organism studies, and other… More | ||
| Entry-Level Modules (ELM) for Training the Genomics Research Workforce (R25-Clinical Trial Not Allowed) | PAR-23-123 | NHGRI | The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that… More | ||
| Technology Development for Single-Molecule Protein Sequencing (R43/R44 Clinical Trial not allowed) | PAR-21-247 | NHGRI | This Funding Opportunity Announcement (FOA) solicits grant applications to catalyze major advances in single-molecule protein sequencing through technology development. The goal of this initiative is… More | ||
| Genome Research Experiences to Attract Talented Undergraduates into Genomic Fields to Enhance Diversity (R25 Clinical Trial Not Allowed) | RFA-HG-22-004 | NHGRI | The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this NHGRI R25 program is to support educational activities… More | ||
| Genome Research Experiences to Attract Talented Undergraduates into the Genomics Field to Enhance Diversity (R25 Clinical Trial Not Allowed) | RFA-HG-21-033 | NHGRI | The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this NHGRI R25 program is to support educational activities… More | ||
| Center for Inherited Disease Research (CIDR) High Throughput Sequencing and Genotyping Resource Access (X01) | PAR-20-230 | NHGRI | The Center for Inherited Disease Research (CIDR) high-throughput genotyping, sequencing and supporting statistical genetics services are designed to aid the identification of genes or genetic… More | ||
| Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21) (Clinical Trial Optional) | PAR-20-255 | NHGRI | This Funding Opportunity Announcement (FOA) invites Exploratory/Developmental Research Grant (R21) applications that propose to study the ethical, legal and social implications (ELSI) of human genome… More | ||
| Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03) Clinical Trial Optional) | PAR-20-257 | NHGRI | This Funding Opportunity Announcement (FOA) invites Small Research Grant (R03) applications to study the ethical, legal and social implications (ELSI) of human genome research. These applications… More | ||
| Ethical, Legal and Social Implications (ELSI) (Research R01 Clinical Trial Optional) | PAR-20-254 | NHGRI | This Funding Opportunity Announcement (FOA) invites Research Project Grant (R01) applications that propose to study the ethical, legal and social implications (ELSI) of human genome research.… More | ||
| Notice of Special Interest: Development of Statistical, Population Genetics and Computational Methods Related to Polygenic Prediction of Health and Disease in Diverse Populations | NOT-HG-20-010 | NHGRI | Notice Special Interest: Development Statistical, Population Genetics Computational Methods Related Polygenic Prediction Health Disease Diverse Populations Notice Number: NOT-HG-20-010 Key Dates… More | ||
| Genomic Curriculum Development for Medical Students (R25 Clinical Trial Not Allowed) | PAR-21-312 | NHGRI | The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this NHGRI R25 program is to support educational activities… More | ||
| New Investigators to Promote Workforce Diversity in Genomics, Bioinformatics, or Bioengineering and Biomedical Imaging Research (R01 Clinical Trial Optional) | RFA-HG-21-041 | NHGRI | This Funding Opportunity Announcement (FOA) solicits R01 grant applications that propose independent research projects that are within the scientific mission areas of the National Human Genome… More | ||
| Supporting Talented Early Career Researchers in Genomics (R01 Clinical Trial Optional) | RFA-HG-22-001 | NHGRI | This Funding Opportunity Announcement is intended to identify and support research projects by exceptionally promising Early Stage Investigators with a long-term career interest in pursuing… More | ||
| NHGRI Predoctoral to Postdoctoral Transition Award for a Diverse Genomics Workforce (F99/K00) | PAR-21-143 | NHGRI | The purpose of the NHGRI Predoctoral to Postdoctoral Transition Award for a Diverse Genomics Workforce (F99/K00) is to support a defined pathway across career stages for talented graduate students… More | ||
| Diversity Centers for Genome Research (U54 Clinical Trials Optional) | RFA-HG-22-026 | NHGRI | The Diversity Center for Genome Research (DCGR) program aims to establish Genomic Research Centers at Minority Serving Institutions (MSIs) as defined in Part 2, section III of the FOA. The MSIs must… More | ||
| Diversity Centers for Genome Research (UG3/UH3 Clinical Trials Optional) | RFA-HG-22-027 | NHGRI | Funding Opportunity PurposeThe full-scale Diversity Centers for Genome Research (DCGR) program aims to establish Genomic Research Centers at Minority Serving Institutions (MSIs) as defined in Part 2… More | ||
| Investigator Initiated Research in Computational Genomics and Data Science (R01 Clinical Trial Not Allowed) | PAR-21-254 | NHGRI | The purpose of this funding opportunity announcement (FOA) is to invite applications for a broad range of research efforts in computational genomics, data science, statistics, and bioinformatics… More | ||
| Investigator Initiated Research in Computational Genomics and Data Science (R21 Clinical Trial Not Allowed) | PAR-21-255 | NHGRI | The purpose of this funding opportunity announcement (FOA) is to invite applications for a broad range of research efforts in computational genomics, data science, statistics, and bioinformatics… More | ||
| Notice of Special Interest (NOSI): Methods Development for Genomic Studies of Genetic Variation, Function, and Disease | NOT-HG-22-007 | NHGRI | The National Human Genome Research Institute (NHGRI) is issuing this Notice of Special Interest (NOSI) to encourage applications that develop novel computational or experimental approaches for… More | ||
| NHGRI Short Courses for Genomics-Related Research Education (R25 Clinical Trial Not Allowed) | PAR-22-095 | NHGRI | The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NHGRI R25 program is to support educational activities… More | ||
| Notice of Special Interest: Development and Implementation of Clinical Informatics Tools to Enhance Patients Use of Genomic Information | NOT-HG-22-011 | NHGRI | The National Human Genome Research Institute (NHGRI) is issuing a Notice of Special Interest (NOSI) to encourage applications to develop and implement patient-facing genomic-based clinical… More | ||
| RESCINDED - Notice of Special Interest (NOSI): Integrative Omics Analysis of NHLBI TOPMed Data (Parent R01 Clinical Trial Not Allowed) | NOT-HL-21-007 | NHLBI | The symptom-based diagnosis and treatment of heart, lung, blood, and sleep (HLBS) diseases has vastly improved in recent years, yet an understanding of the molecular mechanisms underlying many of… More | ||
| Pediatric Heart Network Clinical Research Centers (UM1 Clinical Trial Optional) | RFA-HL-24-001 | NHLBI | The purpose of this FOA is to invite applications to participate as a Clinical Research Center (CRC) in the Pediatric Heart Network (https://www.pediatricheartnetwork.org/). CRCs will be expected to… More | ||
| Limited Competition: Pediatric Heart Network for the Data Coordinating Center (U24 Clinical Trial Not Allowed) | RFA-HL-24-002 | NHLBI | This limited competition Funding Opportunity Announcement (FOA)is to support the Data Coordinating Center (DCC) for the Pediatric Heart Network (https://www.pediatricheartnetwork.org/). Only the… More | ||
| Notice of Special Interest (NOSI): Pulmonary Complications of Hematopoietic Stem Cell Transplantation in Childhood | NOT-HL-20-761 | NHLBI | Notice Special Interest NOSI): Pulmonary Complications Hematopoietic Stem Cell Transplantation Childhood Notice Number: NOT-HL-20-761 Key Dates Release Date: April 27, 2020 First Available Due Date… More | ||
| NHLBI Program Project Applications (P01 Clinical Trials Optional) | PAR-21-088 | NHLBI | The National Heart, Lung, and Blood Institute (NHLBI) Program Project Grant (P01) supports research related to fundamental processes and diseases of the heart, blood and lymphatic vessels, lungs, and… More | ||
| Notice of Special Interest (NOSI): Use of Predictive Analytics to Accelerate Late-Stage Implementation Research to Address Heart, Lung, Blood, and Sleep Disorders | NOT-HL-20-815 | NHLBI | NHLBI is issuing this Notice of Special Interest (NOSI) to leverage existing data resources using Predictive Analytics Implementation Research (PAIR) that utilizes complex and innovative… More | ||
| NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics (R33 Clinical Trial Required) | PAR-21-118 | NHLBI | The objective of this funding opportunity is to support investigator-initiated, phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders… More | ||
| NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics (R61/R33 Clinical Trial Required) | PAR-21-119 | NHLBI | The objective of this funding opportunity is to support investigator-initiated, Phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders… More | ||
| NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional) | PAR-21-079 | NHLBI | Reissue of PAR-19-155 | ||
| Short-Term Research Education Program to Enhance Diversity in Health-Related Research (R25 Clinical Trial Not Allowed) | RFA-HL-22-012 | NHLBI | The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NHLBI R25 program is to support educational activities… More | ||
| NHLBI SBIR Phase IIB Small Market Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional) | RFA-HL-23-008 | NHLBI | The Small Business Innovation Research (SBIR) Program is an important National Institutes of Health (NIH) funding mechanism used to develop innovative solutions that address public health challenges… More | ||
| NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional) | RFA-HL-23-009 | NHLBI | The Small Business Innovation Research (SBIR) Program is an important funding mechanism that the National Institutes of Health (NIH) uses to develop innovative solutions that address public health… More | ||
| T32 Training Program for Institutions That Promote Diversity (T32 Clinical Trial Not Allowed) | RFA-HL-22-001 | NHLBI | The purpose of this funding opportunity announcement (FOA) is to enhance the participation of individuals from nationally underrepresented backgrounds in cardiovascular, pulmonary, hematologic and… More | ||
| Physician Scientist Transition to Independence in Blood Science Research (R00 - Clinical Trial Optional) | RFA-HL-23-003 | NHLBI | The purpose of this limited competition R00 program is to provide physician scientists in blood science with a seamless pathway from a mentored K99/R00 award to investigator independence. Eligible… More | ||
| NHLBI Outstanding Investigator Award (OIA) (R35 Clinical Trial Optional) | RFA-HL-23-004 | NHLBI | The purpose of the NHLBI Outstanding Investigator Award (OIA) is to promote scientific productivity and innovation by providing long-term support and increased flexibility to experienced Program… More | ||
| NHLBI Emerging Investigator Award (EIA) (R35 Clinical Trial Optional) | RFA-HL-23-005 | NHLBI | The purpose of the NHLBI Emerging Investigator Award (EIA) is to promote scientific productivity and innovation by providing long-term support and increased flexibility to experienced Program… More | ||
| Mentored Career Development Award to Promote Faculty Diversity in Biomedical Research (K01 Independent Clinical Trial Required) | RFA-HL-22-010 | NHLBI | This Funding Opportunity Announcement (FOA) invites applications to enhance the pool of highly trained investigators from diverse backgrounds, including those from groups underrepresented in research… More | ||
| Mentored Career Development Award to Promote Faculty Diversity in Biomedical Research (K01 Independent Clinical Trial Not Allowed) | RFA-HL-22-011 | NHLBI | This Funding Opportunity Announcement (FOA) invites applications to enhance the pool of of highly trained investigators from diverse backgrounds , including those from groups underrepresented in… More | ||
| Stimulating Access to Research in Residency (StARR) (R38) | RFA-HL-23-006 | NHLBI | The purpose of this program is to recruit and retain outstanding, postdoctoral-level health professionals who have demonstrated potential and interest in pursuing careers as clinician-investigators.… More | ||
| NHLBI Career Transition Award for Intramural Postdoctoral Fellows and Research Trainees (K22 Independent Clinical Trial Not Allowed) | PAR-22-034 | NHLBI | The purpose of the NHLBI Career Transition Award (K22) program is to provide highly qualified postdoctoral fellows and other doctoral-level researchers still in training in the NHLBI Division of… More | ||
| NHLBI Career Transition Award for Intramural Postdoctoral Fellows and Research Trainees (K22 Clinical Trial Required) | PAR-22-040 | NHLBI | The purpose of the NHLBI Career Transition Award (K22) program is to provide highly qualified postdoctoral fellows in the NHLBI Division of Intramural Research the opportunity to transition their… More | ||
| NHLBI TOPMed: Omics Phenotypes of Heart, Lung, and Blood Disorders (X01 - Clinical Trial Not Allowed) | PAR-22-194 | NHLBI | This Funding Opportunity Announcement (FOA) invites applications to use the NHLBI-funded TransOmics for Precision Medicine (TOPMed) program to generate a large volume of integrated genetic and multi-… More | ||
| Maximizing the Scientific Value of the NHLBI Biologic Biospecimen Repository: Scientific Opportunities for Exploratory Research (R21) | RFA-HL-23-018 | NHLBI | This Funding Opportunity Announcement (FOA) will support meritorious exploratory research relevant to the NHLBI mission (http://www.nhlbi.nih.gov/about/org/mission) using the existing biospecimen… More | ||
| Catalyze: Product Definition Device Prototype Testing and Design Modification, Diagnostic Disease Target Assay Development and Design Characterization, and Research Tool Testing and Validation (R33 - Clinical Trials Not Allowed) | RFA-HL-23-014 | NHLBI | This Funding Opportunity Announcement (FOA) will provide the early stage translational support needed for prototype testing/design modification, assay development for diagnostic disease targets, and… More | ||
| Catalyze: Product Definition for Small Molecules and Biologics - Preliminary Product/Lead Series Identification (R33 - Clinical Trial Not Allowed) | RFA-HL-23-012 | NHLBI | This Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to identify a lead compound series toward development of potential therapeutic agents to treat… More | ||
| Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed) | RFA-HL-23-010 | NHLBI | This Funding Opportunity Announcement (FOA) solicits grant applications to further develop enabling technologies and transformative platforms to catalyze next-generation predictive, diagnostic and… More | ||
| Catalyze: Product Definition Device Prototype Design and Testing, Diagnostic Disease Target Identification and Assay Development, and Research Tool Development (R61/R33 - Clinical Trial Not Allowed) | RFA-HL-23-013 | NHLBI | This Catalyze Product Definition Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to develop and test device prototype designs, identify diagnostic… More | ||
| Catalyze: Product Definition for Small Molecules and Biologics - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 Clinical Trials Not Allowed) | RFA-HL-23-011 | NHLBI | This Catalyze Product Definition Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to identify and characterize potential therapeutic candidates to… More | ||
| Notice of Special Interest (NOSI): IDEA2Health: Innovative Data Evaluation and Analysis to Health | NOT-HL-22-001 | NHLBI | The purpose of this Notice of Special Interest (NOSI) is to inform applicants to the National Heart, Lung, and Blood Institute (NHLBI) of an area of special interest in the development and… More | ||
| Limited Competition: Stimulating Access to Research in Residency Transition Scholar (StARRTS) (K38 Clinical Trial Not Allowed) | RFA-HL-23-007 | NHLBI | The purpose of this program is to provide continued support to Transition Scholars who have successfully matriculated through the NIH Stimulating Access to Research in Residency (StARR) R38 program… More | ||
| Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24 Clinical Trial Required) | PAR-22-193 | NHLBI | This Funding Opportunity Announcement (FOA) supports applications for a collaborating Data Coordinating Center (DCC) for investigator-initiated multi-site clinical trials including efficacy,… More | ||
| Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required) | PAR-22-189 | NHLBI | This Funding Opportunity Announcement (FOA) supports applications to develop and implement investigator-initiated single site clinical trials including efficacy, comparative effectiveness, pragmatic… More | ||
| Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required) | PAR-22-192 | NHLBI | This Funding Opportunity Announcement (FOA) supports applications to develop and implement a Clinical Coordinating Center (CCC) for investigator-initiated multi-site clinical trials including… More | ||
| Limited Competition: Small Grant Program for NHLBI K01/K08/K23/K25 Recipients (R03 Clinical Trial Optional) | RFA-HL-24-005 | NHLBI | The purpose of this funding opportunity announcement (FOA) is to solicit current or recently completed NHLBI K01, K08, K23, and K25 awardees for small grant support to expand their current research… More | ||
| Secondary Analysis of Existing Datasets in Heart, Lung, and Blood Diseases and Sleep Disorders (R21 Clinical Trial Not Allowed) | PAR-23-036 | NHLBI | The goal of this funding opportunity is to stimulate the use of existing human datasets for well-focused secondary analyses to investigate novel scientific ideas or new models, systems, tools,… More | ||
| Notice of Special Interest (NOSI): Integrative Omics Analysis of NHLBI TOPMed Data (Parent R01 Clinical Trial Not Allowed) | NOT-HL-23-067 | NHLBI | The symptom-based diagnosis and treatment of heart, lung, blood, and sleep (HLBS) diseases has vastly improved in recent years, yet an understanding of the molecular mechanisms underlying many of… More | ||
| Notice of Special Interest (NOSI): Development of Functional Assay Sites to Evaluate Candidate -Omics Variants Associated with Heart, Lung, Blood, or Sleep Disease (R01, R41, R42, R43, R44) | NOT-HL-23-066 | NHLBI | Large-scale high-throughput sequencing studies, such as the NHLBIs Trans-Omics for Precision Medicine (TOPMed) program and the NHGRIs Genome Sequencing Program, have identified hundreds of millions… More | ||
| Notice of Special Interest (NOSI): Understanding Sudden Death in the Young Through Research | NOT-HL-22-040 | NHLBI | This Notice of Special Interest (NOSI) highlights interest in receiving grant applications focused on mechanistic, genetic, and other studies to evaluate causes and consequences of and risk factors… More | ||
| Translational Bioinformatics Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimers Disease (R01 Clinical Trial Optional) | PAR-20-156 | NIA | This Funding Opportunity Announcement (FOA) enables data-driven drug repositioning and combination therapy for Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD) by… More | ||
| NIA MSTEM: Advancing Diversity in Aging Research through Undergraduate Education (R25 - Independent Clinical Trial Not Allowed) | PAR-20-317 | NIA | The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that… More | ||
| Interorgan Communication in Aging (U01 Clinical Trial Not Allowed) | RFA-AG-24-005 | NIA | The goal of this RFA is to foster research that examines the molecular mechanisms and consequences of age-related alterations in interorgan communication, thereby modulating the age-related decline… More | ||
| Interventions Testing Program (ITP) Data Coordinating Center (U24 Clinical Trial Not Allowed) | RFA-AG-24-003 | NIA | This Funding Opportunity Announcement (FOA) invitesapplications utilizing a cooperative agreement (U24) mechanism to implement a Data Coordinating Center (DCC) that will provide data storage,… More | ||
| Renewal of the Interventions Testing Program (U01 Clinical Trial Not Allowed) | RFA-AG-24-002 | NIA | This FOA is for the renewal and further development of the Interventions Testing Program (ITP). The ITP tests, under standardized conditions, potential intervention strategies which may delay aging… More | ||
| Roybal Centers for Translational Behavioral Research on Dementia Care, Caregiver Support, and Prevention of Alzheimers Disease and Related Dementias (AD/ADRD) (P30 Clinical Trial Required) | RFA-AG-24-007 | NIA | This Funding Opportunity Announcement (FOA) solicits Edward R. Roybal Centers for translational intervention development research for Alzheimers Disease and Alzheimers Disease related dementias care… More | ||
| Edward R. Roybal Coordinating Center (R24 - Clinical Trial Not Allowed) | RFA-AG-24-008 | NIA | This FOA invites applications from qualified institutions to create a Roybal Center Coordinating Center (CC), serving the needs of the Roybal Centers for Translational Research on Aging program as… More | ||
| Roybal Centers for Translational Research on Aging (P30 Clinical Trial Required) | RFA-AG-24-006 | NIA | This Funding Opportunity Announcement (FOA) solicits Edward R. Roybal Centers for Translation Research in the Behavioral and Social Sciences of Aging. The purpose of the Roybal Centers is to develop… More | ||
| Limited Competition: The Health and Retirement Study and Harmonized Cognitive Assessment Protocol (U01 Clinical Trial Not Allowed) | RFA-AG-24-010 | NIA | The purpose of this limited competition FOA is to solicit an application to continue data collection, development, and dissemination of the Health and Retirement Study (HRS). The HRS is a… More | ||
| Estimating the Monetary Costs of Dementia in the United States (U01 Clinical Trial Not Allowed) | RFA-AG-24-004 | NIA | This funding opportunity announcement (FOA) invites U01 applications to develop national cost of illness estimates for the monetary cost of Alzheimers Disease and Alzheimers disease-related dementias… More | ||
| Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) Real-World Data Platform (U54 Clinical Trial Optional) | RFA-AG-24-009 | NIA | This Funding Opportunity Announcement (FOA) invites applications for the Alzheimers Disease (AD) and Alzheimers Disease-Related Dementias (ADRD) Real-World Data (RWD) Platform initiative. This… More | ||
| Notice to Extend the Expiration Date of PAR-20-156 "Translational Bioinformatics Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimers Disease (R01 Clinical Trial Optional)" | NOT-AG-22-051 | NIA | This Notice informs potential applicants that the expiration date for Funding Opportunity Announcement (FOA)PAR-20-156 "Translational Bioinformatics Approaches to Advance Drug Repositioning and… More | ||
| Notice of Special Interest (NOSI): Maximizing the Scientific Value of Secondary Analyses of Existing Cohorts and Datasets in Order to Address Research Gaps and Foster Additional Opportunities in Aging Research | NOT-AG-21-020 | NIA | The goal of this Notice of Special Interest (NOSI) is to stimulate the use of existing cohorts and datasets for well-focused secondary analyses to investigate novel scientific ideas and/or address… More | ||
| AD/ADRD Clinical Trials Short Course (R25 Independent Clinical Trial Not Allowed) | PAR-21-141 | NIA | It is essential to expand and diversify the skilled AD/ADRD clinical trial workforce. The intent of this Funding Opportunity Announcement (FOA) is to encourage applications that develop creative and… More | ||
| Team Science Approaches Integrating Experimental and Computational Brain Aging Models (R21/R33 Clinical Trial Not Allowed) | RFA-AG-24-018 | NIA | This FOA invites applications proposing to establish new, or significantly expand existing, interdisciplinary collaborations involving both experimental and computational researchers to… More | ||
| Institutional Training Programs to Advance Translational Research on Alzheimer's Disease (AD) and AD-Related Dementias (T32) | PAR-21-112 | NIA | The specific purpose of this Funding Opportunity Announcement (FOA) is to promote the development of a diverse, interdisciplinary workforce needed to conduct translational research on Alzheimer'… More | ||
| Networking/Infrastructure Project for Research on Determinants of Differences Among Human and Nonhuman Primate Species in Life Spans, Life Histories, and Other Aging Related Outcomes, and Prospects for Translation (R61/R33 Clinical Trial Not Allowed) | RFA-AG-24-020 | NIA | The purpose of this Funding Opportunity Announcement (FOA) is to invite R61/R33 applications proposing to establish and conduct a networking and infrastructure project to enhance the development of… More | ||
| Comparative Research on Determinants of Differences Among Human and Nonhuman Primate Species in Life Spans, Life Histories, and Other Aging-Related Outcomes, and Prospects for Translation (R01 Clinical Trial Not Allowed) | RFA-AG-24-019 | NIA | The goal of this Funding Opportunity Announcement (FOA) is to invite R01 applications proposing comparative studies of human and nonhuman primate species with differing life spans to identify factors… More | ||
| Research Coordinating Center on the Exposome and Alzheimer's Disease (AD) and AD-Related Dementias (ADRD): Elucidating the Role of Social and Behavioral Determinants of Health in AD/ADRD Etiology and Disparities (U24 Clinical Trial Not Allowed) | RFA-AG-24-011 | NIA | The purpose of this Funding Opportunity Announcement (FOA) is to invite applications to establish a coordinating center that will serve as a centralized hub for accessing, harmonizing, linking, and… More | ||
| Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Optional) | PAR-21-069 | NIA | This FOA encourages applications at the intersection of HIV and aging by addressing two overarching objectives: 1) to improve understanding of biological, clinical, and socio-behavioral aspects of… More | ||
| Multidisciplinary Studies of HIV/AIDS and Aging (R01 Clinical Trial Optional) | PAR-21-068 | NIA | This FOA encourages applications at the intersection of HIV and aging by addressing two overarching objectives: 1) to improve understanding of biological, clinical, and socio-behavioral aspects of… More | ||
| Dementia Care and Caregiver Support Intervention Research (R01 Clinical Trial Required) | PAR-21-307 | NIA | This Funding Opportunity Announcement (FOA) solicits mechanism-focused dementia care and caregiver support intervention development research at Stages I through V of the NIH Stage Model to address… More | ||
| Pragmatic Trials for Dementia Care and Caregiver Support (R61/R33 Clinical Trial Required) | PAR-21-308 | NIA | This Funding Opportunity Announcement(FOA) will support pragmatic trials within Stage IV of the NIH Stage Model to improve dementia care across multiple dementia care settings that will: (1) be… More | ||
| NIA Advanced Postdoctoral Career Transition Awards to Promote Diversity in Translational Research for AD/ADRD (K99/R00 Clinical Trial Not Allowed) | PAR-21-220 | NIA | The purpose of this Funding Opportunity Announcement (FOA) is to diversify the translational research workforce for Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD).… More | ||
| NIA Academic Leadership Career Award (K07 Independent Clinical Trial Not Allowed) | PAR-21-106 | NIA | The objective of the NIA Academic Leadership Career Award (K07) is to provide support for senior investigators who have the expertise and leadership skills to enhance aging and geriatric research… More | ||
| Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials (R01 Clinical Trial Required) | PAR-20-309 | NIA | This Funding Opportunity Announcement (FOA) invites applications to develop and implement Phase Ib to III clinical trials of promising pharmacological and non-pharmacological interventions that may… More | ||
| Limited Competition: Alzheimers Disease Sequencing Project Follow-Up Study 2.0 (ADSP FUS 2.0): The Diverse Population Initiative (U01 Clinical Trial Not Allowed) | PAR-21-212 | NIA | This Funding Opportunity Announcement (FOA) invites applications specific to sample acquisition, genome wide association studies, whole genome sequencing, quality control checking, variant calling,… More | ||
| Early Stage Investigator Research Using Nonhuman Primate (NHP) Models (R21 Clinical Trial Not Allowed) | PAR-21-109 | NIA | The purpose of this funding opportunity announcement is to provide tailored support for early stage investigators (ESIs) to initiate basic or translational research with nonhuman primates (NHPs).… More | ||
| NIA Expanding Research in AD/ADRD (ERA) Summer Research Education Program (R25 - Independent Clinical Trial Not Allowed) | RFA-AG-24-013 | NIA | It is essential to expand and diversify the skilled Alzheimer's Disease (AD) and Alzheimers Disease Related Dementias (ADRD) research workforce and provide exposure to AD/ADRD research to… More | ||
| NIA Expanding Research in AD/ADRD (ERA) Postbaccalaureate Research Education Program (R25 - Independent Clinical Trial Not Allowed) | RFA-AG-24-012 | NIA | It is essential to expand and diversify the skilled Alzheimers Disease and Alzheimers Disease and Related Dementias (AD/ADRD) research workforce and provide exposure to AD/ADRD research to… More | ||
| NIA Predoctoral Fellowship Award to Promote Diversity in Translational Research for AD/ADRD (F31) | PAR-21-218 | NIA | The purpose of this Funding Opportunity Announcement (FOA) is to diversify the translational research workforce for Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD).… More | ||
| NIA Postdoctoral Fellowship Award to Promote Diversity in Translational Research for AD/ADRD (F32 Clinical Trial Not Allowed) | PAR-21-217 | NIA | The purpose of this Funding Opportunity Announcement (FOA) is to diversify the translational research workforce for Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD).… More | ||
| NIA Renewal and Revision Cooperative Agreements in AD/ADRD Research (U24 Clinical Trial Not Allowed) | PAR-22-110 | NIA | This Funding Opportunity Announcement (FOA) allows for renewal and competitive revision applications, and their resubmissions, for funded U24?Research Resource/Infrastructure?applications?that?… More | ||
| NIA Renewal and Competing Revision Cooperative Agreements in Aging Research (U01 Clinical Trial Optional) | PAR-22-362 | NIA | This Funding Opportunity Announcement (FOA) allows for renewal and competing revision applications, and their resubmissions, for awarded U01 research project cooperative agreements focused on aging… More | ||
| NIA Research and Entrepreneurial Development Immersion (REDI): Entrepreneurship Enhancement Award (R25 Independent Clinical Trial Not Allowed) | PAR-22-226 | NIA | The purpose of the Research and Entrepreneurial Development Immersion (REDI): NIA Entrepreneurship Enhancement Award (R25) is to promote the development of entrepreneurial training programs that are… More | ||
| NIA Renewal and Revision Cooperative Agreements in AD/ADRD Research (U54 Clinical Trial Optional) | PAR-22-077 | NIA | This Funding Opportunity Announcement (FOA) allows for renewal and competing revision applications, and their resubmissions, for funded U54Specialized Centercooperative agreements thatsupportlarge-… More | ||
| NIA Research and Entrepreneurial Development Immersion (REDI): Mentored Entrepreneurial Career Development Award (K01 Clinical Trial Not Allowed) | PAR-22-227 | NIA | The purpose of the NIA Research and Entrepreneurial Development Immersion (REDI): Mentored Entrepreneurial Career Development Award is to provide support and protected time (three to five years) for… More | ||
| Paul B. Beeson Emerging Leaders Career Development Award in Aging (K76 Independent Clinical Trial Not Allowed) | RFA-AG-24-014 | NIA | This Funding Opportunity Announcement (FOA) invites early-stage physicians and other health professional investigators with a commitment to aging and/or aging-related diseases to apply for this award… More | ||
| Transition to Aging Research for Predoctoral Students (F99/K00 Clinical Trial Not Allowed) | RFA-AG-23-016 | NIA | The National Institute on Aging (NIA) invites outstanding graduate students from a wide range of broad research areas who are interested in receiving aging-related postdoctoral training to apply to… More | ||
| Paul B. Beeson Emerging Leaders Career Development Award in Aging (K76 Clinical Trial Required) | RFA-AG-24-015 | NIA | This Funding Opportunity Announcement (FOA) invites early-stage physician and other health professional investigators with a commitment to aging and/or aging-related diseases to apply for this award… More | ||
| Alzheimer's Drug-Development Program (U01 Clinical Trial Optional) | PAR-22-047 | NIA | The goal of this Funding Opportunity Announcement (FOA) is to provide funding support for the pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic drug… More | ||
| Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional) | PAR-22-093 | NIA | The purpose of this Funding Opportunity Announcement (FOA) is to invite applications proposing research on current topics in Alzheimer's disease (AD) and its related dementias (ADRD). Further… More | ||
| Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional) | PAR-22-094 | NIA | The purpose of this Funding Opportunity Announcement (FOA) is to invite applications proposing new tests, animal models, techniques, etc. to advance research on Alzheimer's disease (AD) and its… More | ||
| Pilot Studies for the Spectrum of Alzheimers Disease/Alzheimers Disease-Related Dementias and Age-Related Cognitive Decline (R61 Clinical Trial Optional) | PAR-23-083 | NIA | The purpose of this Funding Opportunity Announcement (FOA) is to 1) invite research grant applications that enable the collection of pilot data to support early stage testing of promising… More | ||
| Early and Late Stage Clinical Trials for the Spectrum of Alzheimers Disease/Alzheimers Related Dementias and Age-Related Cognitive Decline (R01 Clinical Trial Optional) | PAR-23-081 | NIA | The purpose of this Funding Opportunity Announcement (FOA) is to 1) invite applications that propose to develop and implement early to late stage clinical trials of promising pharmacological and non-… More | ||
| NIA Career Transition Award (K22 Independent Clinical Trial Not Allowed) | PAR-21-351 | NIA | The purpose of the NIA Career Transition Award (CTA) is to facilitate the transition of mentored researchers to tenure-track faculty conducting research that advances the mission of NIA. This three-… More | ||
| Integrative Research to Understand the Impact of Sex Differences on the Molecular Determinants of AD Risk and Responsiveness to Treatment (U01 Clinical Trial Optional) | PAR-23-082 | NIA | This Funding Opportunity Announcement (FOA) invites applications that employ integrative experimental and analytical approaches engaging basic and translational/clinical research aimed at developing… More | ||
| Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional) | PAS-22-197 | NIA | This Funding Opportunity Announcement (FOA) invites applications to the National Institute on Aging's (NIA) Small Business Technology Transfer Research (STTR) program. The aim of this FOA is to… More | ||
| Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R43/R44 Clinical Trial Optional) | PAS-22-196 | NIA | This Funding Opportunity Announcement (FOA) invites applications to the National Institute on Aging's (NIA) Small Business Innovation Research (SBIR) program. The aim of this FOA is to support… More | ||
| NIA Program Project Applications (P01 Clinical Trial Optional) | PAR-22-130 | NIA | The National Institute on Aging (NIA) invites the submission of investigator-initiated research program project (P01) applications addressing scientific areas relevant to NIA's mission. Each… More | ||
| Complex Integrated Multi-Component Projects in Aging Research (U19 Clinical Trial Optional) | PAR-22-213 | NIA | This FOA allows for applications that propose large-scale, complex research projects with multiple highly integrated components focused on a common research question relevant to aging. Such projects… More | ||
| Alzheimer's Disease Research Centers (P30 Clinical Trial Not Allowed) | RFA-AG-24-001 | NIA | This Funding Opportunity Announcement (FOA) invites applications from institutions proposing to develop, or renew, an Alzheimer's Disease Research Center (ADRC). The National Institute on Aging… More | ||
| Research Infrastructure Development for Interdisciplinary Aging Studies (R61/R33 - Clinical Trial Optional) | PAR-23-053 | NIA | This FOA invites applications that propose to develop novel research infrastructure that will advance the science of aging in specific areas requiring interdisciplinary partnerships or collaborations… More | ||
| Advanced-Stage Development and Utilization of Research Infrastructure for Interdisciplinary Aging Studies (R33 Clinical Trial Optional) | PAR-23-054 | NIA | This FOA invites applications that propose to develop novel research infrastructure that will advance the science of aging in specific areas requiring interdisciplinary partnerships or collaborations… | ||
| NIA Multi-site Clinical Trial Implementation Grant (R01 Clinical Trial Required) | PAR-23-057 | NIA | This Funding Opportunity Announcement (FOA) invites applications for implementation of investigator-initiated multi-site interventional clinical trials (all phases). The trials should be hypothesis-… More | ||
| Alcohol Treatment and Recovery Research (R34 Clinical Trial Required) | PAR-22-159 | NIAAA | The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R34 Clinical Trial Required mechanism focusing on alcohol treatment and recovery research. This FOA will focus… More | ||
| Alcohol Health Services Research (R01 Clinical Trial Optional) | PAR-22-156 | NIAAA | The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R01 Clinical Trial Optional mechanism focusing on alcohol health services. This FOA will broadly focus on closing… More | ||
| Alcohol Treatment and Recovery Research (R01 Clinical Trial Required) | PAR-22-158 | NIAAA | The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R01 Clinical Trial Required mechanism focusing on alcohol treatment and recovery research. This FOA will focus… More | ||
| Alcohol Health Services Research (R34 Clinical Trial Optional) | PAR-22-157 | NIAAA | The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R34 Clinical Trial Optional mechanism focusing on alcohol health services. This FOA will broadly focus on closing… More | ||
| Notice of Special Interest: Secondary Analyses of Existing Alcohol Research Data | NOT-AA-20-018 | NIAAA | Notice Special Interest: Secondary Analyses Existing Alcohol Research Data Notice Number: NOT-AA-20-018 Key Dates Release Date: August 10, 2020 First Available Due Date: October 05, 2020 Expiration… More | ||
| NIAAA Resource-Related Research Projects (R24 Clinical Trial Not Allowed) | PAR-21-072 | NIAAA | The purpose of the Resource-Related Research Projects (R24) grant is to support investigator-initiated resources designed to provide materials and services to support and advance biomedical research… More | ||
| Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional) | PAR-21-098 | NIAAA | This Funding Opportunity Announcement (FOA) focuses on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD) throughout the lifespan. The intent of this FOA is to support… More | ||
| Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R34 Clinical Trial Optional) | PAR-21-097 | NIAAA | This Funding Opportunity Announcement (FOA) for R34 planning grant applications focuses on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD) throughout the lifespan.… More | ||
| Notice of Special Interest: Genetics of Alcohol Sensitivity and Tolerance | NOT-AA-21-029 | NIAAA | The purpose of this notice of special interest (NOSI) is to provide enhanced understanding of genetic, genomic, and epigenetic factors contributing to biological processes for individual variation in… More | ||
| Mechanisms of Alcohol Tolerance (R21/R33 Clinical Trial Optional) | PAR-21-250 | NIAAA | This funding opportunity announcement (FOA) focuses on sensitivity and tolerance mechanisms underlying the development of alcohol use disorder. The intent of this FOA is to: (1) develop hypotheses… More | ||
| Investigational New Drug (IND)-enabling and Early-Stage Development of Medications to Treat Alcohol Use disorder and Alcohol-Associated Organ Damage (UT1/UT2 Clinical Trial Optional) | PAR-22-103 | NIAAA | This Funding Opportunity Announcement (FOA) supports Small Business Technology Transfer (STTR) applications from small business concerns (SBCs) that propose the development of therapeutic agents for… More | ||
| Investigational New Drug (IND)-enabling and Early-Stage Development of Medications to Treat Alcohol Use disorder and Alcohol-Associated Organ Damage (U43/U44 Clinical Trial Optional) | PAR-22-102 | NIAAA | This Funding Opportunity Announcement (FOA) supports Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that propose the development of therapeutic agents for… More | ||
| Cooperative Centers on Human Immunology (U19 Clinical Trial Optional) | RFA-AI-22-069 | NIAID | This Funding Opportunity Announcement (FOA) seeks to solicit applications from interdisciplinary teams to participate in the Cooperative Centers on Human Immunology (CCHI) program. The program… More | ||
| International Centers of Excellence for Malaria Research (U19 Clinical Trial Not Allowed) | RFA-AI-22-067 | NIAID | This Funding opportunity Announcement (FOA) solicits applications for the International Centers of Excellence for Malaria Research (ICEMR) Program, a multidisciplinary network of centers that will… More | ||
| Notice of Special Interest (NOSI): NIAID Priorities for Biomedical Knowledgebases & Repositories | NOT-AI-20-044 | NIAID | Notice Special Interest NOSI): NIAID Priorities Biomedical Knowledgebases & Repositories Notice Number: NOT-AI-20-044 Key Dates Release Date: June 8, 2020 First Available Due Date: September 25… More | ||
| NIAID Clinical Trial Planning Grant (R34 Clinical Trials Not Allowed) | PAR-20-270 | NIAID | This Funding Opportunity Announcement (FOA) encourages applications that propose to complete planning, design, and preparation of the documentation necessary for implementation of investigator-… More | ||
| Autoimmunity Centers of Excellence, Clinical Research Program (UM1 Clinical Trial Required) | RFA-AI-22-071 | NIAID | The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications to participate in the NIAID Autoimmunity Centers of Excellence (ACE), a cooperative network intended to improve… More | ||
| Autoimmunity Centers of Excellence, Basic Research Program (U19 Clinical Trial Not Allowed) | RFA-AI-22-070 | NIAID | The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications to participate in the NIAID Autoimmunity Centers of Excellence (ACE), a cooperative network intended to improve… More | ||
| Genomics Centers for Infectious Diseases (U19 Clinical Trial Not Allowed) | RFA-AI-23-015 | NIAID | The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for a Genomic Centers for Infectious Disease (GCID) Program. This renewal initiative will support GCIDs to… More | ||
| Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) Centers for Flaviviridae and Togaviridae (U19 Clinical Trial Not Allowed) | RFA-AI-23-019 | NIAID | This Funding Opportunity Announcement (FOA) solicits applications from single institutions or consortia of institutions to participate in the Research and Development of Vaccines and Monoclonal… More | ||
| Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) Network - Coordination and Data Sharing Center (CDSC) (UG3/UH3 Clinical Trial Not Allowed) | RFA-AI-23-021 | NIAID | This Funding Opportunity Announcement (FOA) solicits applications from single institutions or consortia of institutions to establish a Coordination and Data Sharing Center (CDSC) in support of the… More | ||
| Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) Centers for Bunyavirales, Paramyxoviridae and Picornaviridae (U19 Clinical Trial Not Allowed) | RFA-AI-23-020 | NIAID | This Funding Opportunity Announcement (FOA) solicits applications from single institutions or consortia of institutions to participate in the Research and Development of Vaccines and Monoclonal… More | ||
| Consortium for Food Allergy Research: Leadership Center (UM1 Clinical Trial Required) | RFA-AI-22-077 | NIAID | The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for the Leadership Center of the NIAID Consortium for Food Allergy Research (CoFAR). The CoFAR Leadership Center… More | ||
| Consortium for Food Allergy Research: Clinical Research Center (U01 Clinical Trial Required) | RFA-AI-22-076 | NIAID | The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for the Clinical Research Centers (CRC) for the NIAID Consortium for Food Allergy Research (CoFAR). The CoFAR-… More | ||
| Sexually Transmitted Infections (STI) Cooperative Research Centers (CRC): Vaccine Development (U01 Clinical Trial Not Allowed) | RFA-AI-23-008 | NIAID | The purpose of this Funding Opportunity Announcement (FOA) is to advance vaccine candidates for gonorrhea, chlamydia and syphilis by supporting IND-enabling activities. Applications must include a… More | ||
| Exploratory Data Science Methods and Algorithm Development in Infectious and Immune-mediated Diseases (R21 Clinical Trial Not Allowed) | RFA-AI-21-035 | NIAID | The purpose of this Funding Opportunity Announcement (FOA) is to support exploratory research focused on developing innovative methods and algorithms in biomedical computing, informatics, and data… More | ||
| Early-Stage Development of Data Science Technologies for Infectious and Immune-mediated Diseases (U01 Clinical Trial Not Allowed) | RFA-AI-21-020 | NIAID | The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for the development of enabling data science technologies to improve the acquisition, management, analysis,… More | ||
| Global Infectious Disease Research Administration Development Award for Low-and Middle-Income Country Institutions (G11 Clinical Trial Not Allowed) | PAR-21-037 | NIAID | The purpose of this Funding Opportunity Announcement (FOA) is to invite applications from research institutions in low- to middle-income countries (LMIC) to provide senior administrators from these… More | ||
| Defining Mechanisms of HIV Induced Inflammation and Immune Activation During Suppressive Antiretroviral Therapy (ART) (R01 Clinical Trial Not Allowed) | RFA-AI-23-018 | NIAID | This Funding Opportunity Announcement (FOA) encourages research focused on defining the molecular mechanisms by which HIV proteins and/or nucleic acids induce inflammation, immune activation and HIV… More | ||
| NIAID Research Education Program Advancing the Careers of a Diverse Research Workforce (R25 Clinical Trial Not Allowed) | PAR-21-258 | NIAID | The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this NIAID R25 program is to support educational activities… More | ||
| Limited Competition: Exploratory and Developmental Research Grant Program for NIAID K01/K08/K23 Recipients (R21 Clinical Trial Not Allowed) | PAR-20-291 | NIAID | The National Institute of Allergy and Infectious Diseases (NIAID) announces a program that provides NIAID-supported K01, K08, and K23 recipients with the opportunity to apply for Exploratory and… More | ||
| Limited Competition: Small Research Grant Program for NIAID K01/K08/K23 Recipients (R03 Clinical Trial Not Allowed) | PAR-20-290 | NIAID | The National Institute of Allergy and Infectious Diseases (NIAID) announces a program that provides NIAID-supported K01, K08, and K23 recipients with the opportunity to apply for Small Research Grant… More | ||
| NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required) | PAR-21-082 | NIAID | This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to implement investigator-… More | ||
| NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required) | PAR-21-083 | NIAID | This Funding Opportunity Announcement (FOA) encourages cooperative agreement applications for implementation of investigator-initiated, high-risk clinical trials and mechanistic studies associated… More | ||
| Notice of Special Interest (NOSI): Administrative Supplements for R25 Data Science Training for Infectious and Immune-mediated Disease Research | NOT-AI-23-010 | NIAID | The purpose of this Notice of Special Interest (NOSI) is to highlight the interest of participating NIH institutes and centers (ICs) to enhance existing NIH research Education (R25) awards with data… More | ||
| Notice of Special Interest (NOSI): Harnessing Big Data to Halt HIV | NOT-AI-21-054 | NIAID | The purpose of this Notice of Special Interest (NOSI) is to promote and support innovative methods in Big Data Science (BDS) to identify unappreciated biomedical, behavioral, social patterns and… More | ||
| NIAID Research Education Program (R25 Clinical Trial Not Allowed) | PAR-22-134 | NIAID | The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this National Institute of Allergy and infectious Diseases (… More | ||
| Next Generation Multipurpose Prevention Technologies (NGM) (R01 Clinical Trial Optional) | PAR-22-222 | NIAID | The objective of this Funding Opportunity Announcement (FOA) is to support the continued development of new and innovative on-demand, event-driven, and long-acting (systemic and non-systemic)… More | ||
| Transgender People: Immunity, Prevention, and Treatment of HIV and STIs (R21 Clinical Trial Not Allowed) | PAR-22-186 | NIAID | The purpose of this Funding Opportunity Announcement (FOA) is to support hypothesis-generating research in transgender people with the objective of characterizing the biological and immunological… More | ||
| Identifying Host Cell Death Pathway Targets for Host-Directed Therapies for Treatment of Mtb and Mtb/HIV Co-Infection (R01 Clinical Trial Not Allowed) | PAR-22-223 | NIAID | The purpose of this Funding Opportunity Announcement (FOA) is to support mechanistic studies on host cell death pathways and immune responses to Mycobacterium tuberculosis (Mtb) and Mtb/HIV co-… More | ||
| NIAID Career Transition Award (K22 Independent Clinical Trial Not Allowed) | PAR-22-075 | NIAID | The purpose of the NIAID Career Transition Award (CTA) program is to assist postdoctoral fellows' transition to positions of assistant professor or equivalent and initiate a successful… More | ||
| Resources Access for Preclinical Integrated Drug Development (RAPIDD) Program (X01 Clinical Trial Not Allowed) | PAR-22-185 | NIAID | The purpose of this FOA is to provide a method for investigators to request gap filling preclinical services to academic and private institutions to assist with product development efforts and… More | ||
| Integrated Preclinical / Clinical AIDS Vaccine Development Program (IPCAVD) (U19 Clinical Trial Not Allowed) | PAR-23-033 | NIAID | The purpose of this Funding Opportunity Announcement (FOA) is to support translation of advanced HIV-1 vaccine candidates from pre-clinical studies through different phases of process and product… More | ||
| Centers for AIDS Research (P30 Clinical Trial Not Allowed) | PAR-23-116 | NIAID | The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for the Centers for AIDS Research (CFAR) program to provide administrative and shared research support to enhance… More | ||
| Developmental Centers for AIDS Research (P30 Clinical Trial Not Allowed) | PAR-23-117 | NIAID | The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for the Developmental Centers for AIDS Research (D-CFAR) program to provide administrative and shared research… More | ||
| NIH Medical Scientist Partnership Program (FM1 Clinical Trial Not Allowed) | PAR-23-109 | NIAID | The purpose of the MSPP is to develop a diverse pool of combined-degree students (e.g., MD/PhD, DDS/PhD, DVM/PhD) who have conducted their PhD dissertation research at research laboratories in the… More | ||
| NIAID Research Opportunities for New and "At-Risk" Investigators to Promote Workforce Diversity (R01 Clinical Trial Optional) | PAR-22-241 | NIAID | This Funding Opportunity Announcement (FOA) solicits R01 grant applications that propose independent research projects that are within the scientific mission areas of the participating NIH Institutes… More | ||
| NIAID Investigator Initiated Program Project Applications (P01 Clinical Trial Not Allowed) | PAR-22-225 | NIAID | This Funding Opportunity Announcement (FOA) invites submission of investigator-initiated Program Project (P01) applications. The proposed programs should address scientific areas relevant to the… More | ||
| NIAID Resource-Related Research Projects (R24 Clinical Trial Not Allowed) | PAR-23-065 | NIAID | This Funding Opportunity Announcement (FOA), issued by the National Institute of Allergy and Infectious Diseases (NIAID), invites applications for investigator-initiated Resource-Related Research… More | ||
| NIAID Physician-Scientist Pathway to Independence Award (K99/R00 Independent Clinical Trial Not Allowed) | PAR-23-071 | NIAID | The purpose of the NIAID Physician-Scientist Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented independent physician-scientists. This… More | ||
| Mentored Career Development Program for Early Stage Investigators Using Nonhuman Primate Research Models (K01 Independent Clinical Trial Not Allowed) | PAR-23-073 | NIAID | The purpose of this Funding Opportunity Announcement (FOA) is to provide early-stage investigators with support and protected time (up to five years) for intensive, research-focused career… More | ||
| NIAID Physician-Scientist Pathway to Independence Award (K99/R00 Clinical Trial Required) | PAR-23-070 | NIAID | The purpose of the NIAID Physician-Scientist Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented independent physician-scientists. This… More | ||
| Investigator Initiated Extended Clinical Trial (R01 Clinical Trial Required) | PAR-23-084 | NIAID | This Funding Opportunity Announcement (FOA) invites applications for implementation of investigator-initiated clinical trials requiring an extended project period of 6 or 7 years. The trials can be… More | ||
| NIAMS Skin Biology and Diseases Resource-based Centers (P30 - Clinical Trial Not Allowed) | RFA-AR-24-001 | NIAMS | NIAMS Skin Biology and Diseases Resource-based Centers (P30 - Clinical Trial Not Allowed) | ||
| NIAMS Resource-based Centers for Bone, Muscle and Orthopaedic Research (P30 - Clinical Trial Not Allowed) | RFA-AR-24-002 | NIAMS | NIAMS Resource-based Centers for Bone, Muscle and Orthopaedic Research (P30 - Clinical Trial Not Allowed) | ||
| Notice of Special Interest: Promoting Research on Mechanisms of Pathogenesis and Pathophysiology of Atypical Femoral Fracture (AFF) and Osteonecrosis of the Jaw (ONJ) | NOT-AR-21-006 | NIAMS | Notice Special Interest: Promoting Research Mechanisms Pathogenesis Pathophysiology Atypical Femoral Fracture AFF) Osteonecrosis the Jaw ONJ) Notice Number: NOT-AR-21-006 Key Dates Release Date:… More | ||
| NIAMS Clinical Trial Planning Grant (R34) - Clinical Trial Not Allowed | PAR-22-205 | NIAMS | NIAMS Clinical Trial Planning Grant (R34) - Clinical Trial Not Allowed Re-Issue | ||
| Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 Clinical Trial Not Allowed) | PAR-21-053 | NIAMS | Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 Clinical Trial Not Allowed) | ||
| NIAMS Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required) | PAR-21-036 | NIAMS | NIAMS Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required) | ||
| Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R21 Clinical Trial Required) | PAR-21-045 | NIAMS | Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R21 Clinical Trial Required) | ||
| Limited Competition: Promoting a Basic Understanding of Chemical Threats to Skin (R34 Clinical Trial Not Allowed) | PAS-21-245 | NIAMS | Promoting a Basic Understanding of Chemical Threats to Skin (R34 Clinical Trial not allowed) | ||
| Limited Competition: Small Grant Program for NIAMS K01, K08, K23, and K25 Recipients (R03) (Clinical Trials Not Allowed) | PAR-22-119 | NIAMS | Limited Competition: Small Grant Program for NIAMS K01, K08, K23, and K25 Recipients (R03) | ||
| Late-Stage Translation of Biomedical and Behavioral Research Results in Arthritis and Musculoskeletal and Skin Diseases from Academic/Non-profit Lab to Marketplace (SBIR [R43/R44] Clinical Trial Not Allowed) | PAR-23-032 | NIAMS | Late-Stage Translation of Biomedical and Behavioral Research Results in Arthritis and Musculoskeletal and Skin Diseases from Academic/Non-profit Lab to Marketplace (SBIR [R43/R44] Clinical Trial Not… More | ||
| Ancillary Studies to Ongoing Clinical Projects (R01 Clinical Trial Not Allowed) | PAR-23-025 | NIAMS | Ancillary Studies to Ongoing Clinical Projects (R01 Clinical Trial Not Allowed) | ||
| Ancillary Studies to Ongoing Clinical Projects (R21 Clinical Trial Not Allowed) | PAR-23-026 | NIAMS | Ancillary Studies to Ongoing Clinical Projects (R21 Clinical Trial Not Allowed) | ||
| National Centers for Biomedical Imaging and Bioengineering (NCBIB) (P41 Clinical Trials Optional) | PAR-20-169 | NIBIB | This Funding Opportunity Announcement (FOA) encourages grant applications for Biomedical Technology Resource Centers (BTRCs). BTRCs are national resource centers for conducting research and… More | ||
| NIBIB Biomaterials Network Technology Development Coordinating Center (U24 Clinical Trial Not Allowed) | RFA-EB-23-002 | NIBIB | The purpose of this funding opportunity announcement (FOA) is to | ||
| Research on Bioethical Issues Related to Bionic and Robotic Device Development and Translation (R21 Clinical Trial Optional) | RFA-EB-23-001 | NIBIB | Ethical considerations are intrinsic to the conduct of robotic and bionic device research. This Funding Opportunity Announcement (FOA) invites applications that propose research on ethical questions… More | ||
| BRAIN Initiative: Transformative Brain Non-invasive Imaging Technology Development (UG3/UH3 Clinical Trial Not Allowed) | RFA-EB-22-003 | NIBIB | This Funding Opportunity Announcement (FOA) solicits applications for team-centric development and validation of innovative non-invasive imaging technologies that could have a transformative impact… More | ||
| Technology Development to Reduce Health Disparities (R01 Clinical Trial Optional) | RFA-EB-21-001 | NIBIB | The purpose of this funding opportunity is to reduce health disparities through the development and translation of appropriate medical technologies. The NIH defines health disparities as differences… More | ||
| Team-Based Design in Biomedical Engineering Education (R25 Clinical Trial Not Allowed) | PAR-22-000 | NIBIB | The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NIBIB R25 program is to support educational activities… More | ||
| Bioengineering Partnerships with Industry (U01 Clinical Trial Optional) | PAR-22-123 | NIBIB | This Funding Opportunity Announcement (FOA) solicits applications from research partnerships formed by academic and industrial investigators to accelerate the development and adoption of promising… More | ||
| HEAL Initiative: Translational Development of Diagnostic and Therapeutic Devices (R18 Clinical Trial Not Allowed) | RFA-EB-22-002 | NIBIB | The purpose of this Funding Opportunity Announcement (FOA) is to develop clinical-grade prototypes intended for use as safe, effective, and non-addictive device-based technologies and approaches to… More | ||
| Trailblazer Award for New and Early Stage Investigators (R21 Clinical Trial Optional) | PAR-24-022 | NIBIB | This Trailblazer Award is an opportunity for NIH-defined New and Early Stage Investigators (https://grants.nih.gov/policy/early-investigators/index.htm) to pursue research programs that integrate… More | ||
| Physiomimetics and Organoids for Reproductive Health (R01 Clinical Trial Not Allowed) | RFA-HD-23-024 | NICHD | This Funding Opportunity Announcement (FOA) invites grant applications to develop physiomimetic platforms and organoid culture systems for studies of the female reproductive tract and gametogenesis (… More | ||
| Pediatric Critical Care and Trauma Scientist Development Program (K12 Clinical Trial Optional) | RFA-HD-24-001 | NICHD | The purpose of this Funding Opportunity Announcement (FOA) is to invite applications to support a national program of mentored advanced career development and training in research for junior faculty… More | ||
| Physiomimetics and Organoids for Reproductive Health (R21 Clinical Trial Not Allowed) | RFA-HD-23-025 | NICHD | This Funding Opportunity Announcement (FOA) invites grant applications to develop physiomimetic platforms and organoid culture systems for studies of the female reproductive tract and gametogenesis (… More | ||
| Development of Novel Nonsteroidal Contraceptive Methods (R61/R33 - Clinical Trial Not Allowed) | RFA-HD-24-002 | NICHD | The purpose of this funding opportunity announcement (FOA) is to support and facilitate multidisciplinary research approaches for the development of novel nonsteroidal contraceptive products for men… More | ||
| Using Archived Data and Specimen Collections to Advance Maternal and Pediatric HIV/AIDS Research (R21 - Clinical Trial Not Allowed) | RFA-HD-24-006 | NICHD | The purpose of this Funding Opportunity Announcement (FOA) is to address the needs of the maternal and pediatric HIV scientific community for research data translation and sharing. This initiative… More | ||
| NICHD Biomedical Informatic Resource Centers Grants (P41 Clinical Trial Not Allowed) | PAR-20-126 | NICHD | The purpose of this Funding Opportunity Announcement (FOA) is to support the continued operation, enhancement, and dissemination of unique database resources and/or bioinformatics tools that are of… More | ||
| Notice of Special Interest (NOSI): Climate Change and Health Administrative Supplements | NOT-HD-23-006 | NICHD | The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), in partnership with the National Institute of Environmental Health Science (NIEHS), Fogarty International… More | ||
| Fertility Status as a Marker for Overall Health (R21 Clinical Trial Not Allowed) | PAR-20-282 | NICHD | T?he purpose of this funding opportunity announcement (FOA) is to support exploratory/developmental research that explores the premise that fertility status can be a marker for overall health.… More | ||
| Fertility Status as a Marker for Overall Health (R01 Clinical Trial Optional) | PAR-20-281 | NICHD | The purpose of this funding opportunity (FOA) is to support research that explores the premise that fertility status can be a marker for overall health. Chronic conditions such as concer, diabetes,… More | ||
| Opportunities for Advancing Limb Regeneration Research (R01 Clinical Trial Not Allowed) | RFA-HD-24-004 | NICHD | The purpose of this Funding Opportunity Announcement (FOA) is to promote transformative basic research on limb regeneration using animal models. The primary focus is on gaining insight into the bodys… More | ||
| Population Dynamics Centers Research Infrastructure Program FY 2024 (P2C Clinical Trial Not Allowed) | RFA-HD-24-008 | NICHD | The goal of this funding opportunity announcement (FOA) is to advance the field of population dynamics research by increasing research impact, innovation, and productivity; developing junior… More | ||
| Development of the Fetal Immune System (R01 Clinical Trial Not Allowed) | PAR-20-298 | NICHD | The purpose of this Funding Opportunity Announcement (FOA) is to understand the contribution of specific elements of maternal molecular and cellular factors that can control and effect the… More | ||
| Multipurpose Prevention Technology: Novel Systemic Options for Young Adults (R41/R42 Clinical Trial Not Allowed) | PAR-21-298 | NICHD | The objective of this Funding Opportunity Announcement (FOA) is to support the development of new and innovative long-acting systemic and non-systemic multipurpose prevention technologies (MPT). It… More | ||
| Multipurpose Prevention Technology: Novel Systemic Options for Young Adults (R43/R44 Clinical Trial Not Allowed) | PAR-21-297 | NICHD | The objective of this Funding Opportunity Announcement (FOA) is to support the development of new and innovative long-acting systemic and non-systemic multipurpose prevention technologies (MPT). It… More | ||
| Pre-application: Opportunities for Collaborative Research at the NIH Clinical Center (X02 Clinical Trial Optional) | PAR-21-342 | NICHD | The goal of this program is to support collaborative translational research projects aligned with NIH efforts to enhance the translation of basic biological discoveries into clinical applications… More | ||
| Natural History of Disorders Screenable in the Newborn Period (R01 Clinical Trial Optional) | PAR-21-115 | NICHD | This funding opportunity announcement (FOA) encourages applications that propose to develop studies that will lead to a broad understanding of the natural history of disorders that already do or… More | ||
| Opportunities for Collaborative Research at the NIH Clinical Center (U01 Clinical Trial Optional) | PAR-21-343 | NICHD | The goal of this program is to support collaborative translational research projects aligned with NIH efforts to enhance the translation of basic biological discoveries into clinical applications… More | ||
| NICHD Small Research Grant Program (R03 Basic Experimental Studies with Humans Required) | PA-21-231 | NICHD | The NICHD Small Research Grant Program (Clinical Trial Required) supports clinical trials that fall within the NICHD mission. This funding opportunity announcement is for basic science… More |
||
| Pediatric Immune System Ontogeny and Development (INTEND) (R01 Clinical Trial Not Allowed) | PAR-21-248 | NICHD | The purpose of this Funding Opportunity Announcement (FOA) is to correlate immune systemdevelopment patterns between two or more age groups- neonates, infants, and children and adolescents and… More | ||
| NICHD Small Research Grant Program (R03 Clinical Trial Required) | PA-21-221 | NICHD | The NICHD Small Research Grant Program (Clinical Trial Required) supports clinical trials that fall within the NICHD mission. | ||
| Notice of Special Interest (NOSI) - Emerging and Existing Issues of Coronavirus Disease 2019 (COVID-19) Research Related to the Health and Well-Being of Women, Children and Individuals with Physical and/or Intellectual Disabilities | NOT-HD-22-002 | NICHD | The purpose of this funding opportunity is to provide an avenue for researchers to pursue funding to conduct research addressing these emerging and existing COVID-related issues. The goal of this… More | ||
| Advancing Methods for Safe, Noninvasive, Real Time Assessment of Placenta Development and Function Across Pregnancy (R01 Clinical Trial Not Allowed) | PAR-22-237 | NICHD | This Funding Opportunity Announcement (FOA) invites grant applications that seek to advance or clinically validate emerging novel approaches for the development of safe, real-time, non-invasive (or… More | ||
| Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R01 - Clinical Trial Optional) | PAR-21-353 | NICHD | This FOA encourages research relevant to the development of novel screening approaches and/or therapeutic interventions for potentially fatal or disabling conditions that have been identified through… More | ||
| Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R03 - Clinical Trial Optional) | PAR-21-354 | NICHD | This FOA encourages research relevant to the development of novel screening approaches and/or therapeutic interventions for potentially fatal or disabling conditions that have been identified through… More | ||
| Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R21 - Clinical Trial Optional) | PAR-21-355 | NICHD | This FOA encourages research relevant to the development of novel screening approaches and/or therapeutic interventions for potentially fatal or disabling conditions that have been identified through… More | ||
| Advancing Methods for Safe, Noninvasive, Real Time Assessment of Placenta Development and Function Across Pregnancy (R21 Clinical Trial Not Allowed) | PAR-22-236 | NICHD | This Funding Opportunity Announcement (FOA) invites grant applications that seek to advance or clinically validate emerging novel approaches for the development of safe, real-time, non-invasive (or… More | ||
| Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Required) | PAR-21-357 | NICHD | The purpose of the Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools is to support small scale research grants at institutions that do not receive… More | ||
| NCMRR Early Career Research Award (R03 Clinical Trial Optional) | PAR-23-029 | NICHD | The National Center for Medical Rehabilitation Research (NCMRR) Early Career Research (ECR) Award (R03) is intended to support both basic and clinical research from rehabilitation scientists who are… More | ||
| Biological Testing Facility (X01 Clinical Trial Not Allowed) | PAR-23-128 | NICHD | The purpose of this funding opportunity announcement (FOA) is to provide investigators with a mechanism to request services from this facility that would advance their contraceptive development… More | ||
| Screening and Functional Validation of Human Birth Defects Genomic Variants (R01 Clinical Trial Not Allowed) | PAR-21-229 | NICHD | Rapid advances in genotyping and next generation sequencing technologies have led to the identification of genetic variants that are associated with a wide variety of congenital defects including… More | ||
| NICHD Research Education Programs (R25 Clinical Trial Not Allowed) | PAR-22-224 | NICHD | This FOA will support creative educational activities that focus primarily on research skills development. . Although activities focused primarily on mentoring activities or professional skills… More | ||
| Advancing Research to Understand Congenital Malformations (R01 Clinical Trial Not Allowed) | PAR-22-215 | NICHD | The purpose of this funding opportunity announcement (FOA) is to support innovative research that will inform our understanding of the mechanisms underlying the formation of structural birth defects… More | ||
| Archiving and Documenting Child Health and Human Development Data Sets (R03 Clinical Trial Not Allowed) | PAR-22-261 | NICHD | The purpose of this funding opportunity announcement (FOA) is to invite R03 applications to support archiving and documenting existing data sets in order to enable secondary analysis of these data by… More | ||
| In-Depth Phenotyping and Research Using IMPC-Generated Knockout Mouse Strains Exhibiting Embryonic or Perinatal Lethality or Subviability (R01 Clinical Trial Not Allowed) | PAR-23-074 | NICHD | The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to phenotype and/or perform research on embryonic lethal knockout (KO) mouse strains being generated through… More | ||
| Small Research Grants for Analyses of Gabriella Miller Kids First Pediatric Research Data (R03 Clinical Trial Not Allowed) | PAR-23-075 | NICHD | The NIH Common Fund has established the Gabriella Miller Kids First Pediatric Research Program (Kids First) to develop a pediatric research data resource populated by genome sequence and phenotypic… More | ||
| Multisite Clinical Research: Leveraging Network Infrastructure to Advance Research for Women, Children, Pregnant and Lactating Individuals, and Persons with Disabilities (U01 Clinical Trial Optional) | PAR-23-037 | NICHD | The purpose of this funding opportunity announcement (FOA) is to invite applications for multisite clinical trials and observational studies developed in conjunction with NICHD Networks that will be… More | ||
| Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional) | PAR-23-131 | NICHD | The purpose of this funding opportunity announcement (FOA) is to support translational and clinical research to (1) advance precision medicine in pregnant persons, lactating persons, and children… More | ||
| Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R01 Clinical Trial Optional) | PAR-23-130 | NICHD | The purpose of this funding opportunity announcement (FOA) is to support translational and clinical research to (1) advance precision medicine in pregnant persons, lactating persons, and children… More | ||
| NIDA Program Project Grant Applications (P01 Clinical Trial Optional) | PAR-22-201 | NIDA | This Funding Opportunity Announcement (FOA) announces the availability of support for collaborative research by multi-disciplinary teams which is of high priority to NIDA and leads to synergistic… More | ||
| Notice of Special Interest (NOSI): Biomarkers and Biotypes of Drug Addiction | NOT-DA-20-012 | NIDA | Notice Special Interest NOSI): Biomarkers Biotypes Drug Addiction Notice Number: NOT-DA-20-012 Key Dates Release Date: January 06, 2020 First Available Due Date: February 05, 2020 Expiration Date:… More | ||
| Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional) | PAR-19-282 | NIDA | This Funding Opportunity Announcement (FOA) uses a R61/R33 Phased Innovation Award mechanism to support clinical research applications that are exploratory and developmental in nature and focus on… More | ||
| Extracellular RNA carrier subclasses in processes relevant to Substance Use Disorders or HIV infection (R01- Clinical Trial Not Allowed) | PAR-20-147 | NIDA | The purpose of this FOA is to encourage research investigating the roles of extracellular RNA (exRNA) carrier subclasses in biological processes relevant to substance use disorders (SUDs) and/or HIV… More | ||
| Substance Use/Substance Use Disorder Dissertation Research Award (R36 - Clinical Trials Optional) | PA-20-208 | NIDA | The goal of this FOA is to support doctoral candidates from a variety of academic disciplines for up to two years for the completion of the doctoral dissertation research project. Research projects… More | ||
| NIDA Small Research Grant Program (R03 Clinical Trial Required) | PA-20-146 | NIDA | The NIDA Small Research Grant Program supports small research projects that can be carried out in a short period of time with limited resources. This program supports different types of projects… More | ||
| Extracellular RNA carrier subclasses in processes relevant to Substance Use Disorders or HIV infection (R21- Clinical Trial Not Allowed) | PAR-20-148 | NIDA | The purpose of this FOA is to encourage research investigating the roles of extracellular RNA (exRNA) carrier subclasses in biological processes relevant to substance use disorders (SUDs) and/or HIV… More | ||
| NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UG3/UH3 Clinical Trial Optional) | PAR-21-092 | NIDA | The purpose of this award is to support outstanding basic and/or clinical researchers with the vision and expertise to translate research discoveries into medications for the treatment of Substance… More | ||
| Mechanisms and Targets at the Intersection of HIV and Substance Use (R21 Clinical Trials Not Allowed) | RFA-DA-24-014 | NIDA | The purpose of this FOA is to support basic research on signaling pathways and mechanisms including HIV-host protein interactions and post-translational modifications by which addictive drugs and HIV… More | ||
| Mechanisms and Targets at the Intersection of HIV and Substance Use (R01 Clinical Trials Not Allowed) | RFA-DA-24-013 | NIDA | The purpose of this FOA is to support basic research on signaling pathways and mechanisms including HIV-host protein interactions and post-translational modifications by which addictive drugs and HIV… More | ||
| Device-Based Treatments for Substance Use Disorders (UG3/UH3, Clinical Trial Optional) | PAR-20-279 | NIDA | The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the development of devices to treat Substance Use Disorders (SUDs). The continuing advances in technologies offer… More | ||
| Leveraging Big Data Science to Elucidate the Mechanisms of HIV Activity and Interaction with Substance Use Disorder (R01 Clinical Trials Not Allowed) | RFA-DA-24-008 | NIDA | The purpose of this FOA is to attract data and computational scientists to propose novel ways to integrate data of different types and scales to allow new types of analysis. It is expected that with… More | ||
| Leveraging Big Data Science to Elucidate the Mechanisms of HIV Activity and Interaction with Substance Use Disorder (R21 Clinical Trials Not Allowed) | RFA-DA-24-009 | NIDA | The purpose of this FOA is to attract data and computational scientists to propose novel ways to integrate data of different types and scales to allow new types of analysis. It is expected that with… More | ||
| New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R01 Clinical Trial Required) | PAR-20-273 | NIDA | The purpose of this FOA is to support the testing of enhanced models of care that optimally integrate HIV, addiction, and primary care services. | ||
| Pathogenic Mechanisms influencing Blood Brain Barrier function in HIV and Substance Use Disorders (R01 Clinical Trial Optional) | RFA-DA-23-012 | NIDA | The blood brain barrier (BBB) is a target of both the HIV virus and substances of abuse. It is a site of entry for HIV infected monocytes and macrophages that can traverse the BBB either… More | ||
| Implementing Comprehensive HIV services in Syringe Service Program (SSP) Settings (R01 - Clinical Trial Required) | RFA-DA-23-006 | NIDA | There has been a substantial increase in the number of syringe service programs (SSPs) in the US and the range of these settings has become broader, with many now located in health department or… More | ||
| New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R34 - Clinical Trial Optional ) | PAR-20-274 | NIDA | This funding opportunity announcement will support the development and testing of enhanced models of care that are able to optimally integrate HIV, addiction, and primary care services. | ||
| Implementing Comprehensive HIV services in Syringe Service Program (SSP) Settings (R34 - Clinical Trial Required) | RFA-DA-23-007 | NIDA | There has been a substantial increase in the number of syringe service programs (SSPs) in the US and the range of these settings has become broader, with many now located in health department or… More | ||
| Notice of Special Interest (NOSI): Harnessing computational tools for sophisticated analyses of Substance Use Disorder-related behaviors | NOT-DA-20-017 | NIDA | Notice Special Interest NOSI): Harnessing computational tools sophisticated analyses Substance Disorder-related behaviors Notice Number: NOT-DA-20-017 Key Dates Release Date: March 5, 2020 First… More | ||
| Research to Improve Native American Health (R21 Clinical Trials Optional) | PAR-20-214 | NIDA | The purpose of this funding opportunity announcement (FOA) is to support developmental/exploratory studies in preparation for health promotion, disease prevention, treatment, or treatment services… More | ||
| Notice of Special Interest (NOSI): Advancing Research on SUD through Computational Neuroscience | NOT-DA-20-022 | NIDA | Notice Special Interest NOSI): Advancing Research SUD through Computational Neuroscience Notice Number: NOT-DA-20-022 Key Dates Release Date: 05, 2020 First Available Due Date: June 05, 2020… More | ||
| Notice of Special Interest (NOSI):Sleep and Substance Use Disorders | NOT-DA-20-021 | NIDA | Notice Special Interest NOSI): Sleep Substance Disorders Notice Number: NOT-DA-20-021 Key Dates Release Date: March 25, 2020 First Available Due Date: June 05, 2020 Expiration Date: September 08,… More | ||
| Notice of Special Interest (NOSI): Cannabis, Prescription Opioid, or Prescription Benzodiazepine Drug Use Among Older Adults | NOT-DA-20-014 | NIDA | Notice Special Interest NOSI): Cannabis, Prescription Opioid, Prescription Benzodiazepine Drug Among Older Adults Notice Number: NOT-DA-20-014 Key Dates Release Date: April 22, 2020 First Available… More | ||
| Notice of Special Interest (NOSI): Human Molecular Genetics of Substance Use Disorders | NOT-DA-20-030 | NIDA | Notice Special Interest NOSI): Human Molecular Genetics Substance Disorders Notice Number: NOT-DA-20-030 Key Dates Release Date: March 5, 2020 First Available Due Date: une 05, 2020 Expiration Date… More | ||
| Notice of Special Interest (NOSI): Mentored Career Development Award in Large-Scale Clinical Study Development and Analysis | NOT-DA-20-006 | NIDA | Notice Special Interest NOSI): Mentored Career Development Award Large-Scale Clinical Study Development Analysis Notice Number: NOT-DA-20-006 Key Dates Release Date: March 5, 2020 First Available… More | ||
| Intervention Research to Improve Native American Health (R01 Clinical Trial Optional) | PAR-20-238 | NIDA | The purpose of this funding opportunity announcement (FOA) is to support research on interventions to improve health in Native American (NA) populations. This includes 1) etiologic research, where… More | ||
| Notice of Special Interest (NOSI): Going Global: Using Gene Network Analyses to Understand the Etiology of SUD | NOT-DA-20-020 | NIDA | Notice Special Interest NOSI): Going Global: Using Gene Network Analyses Understand Etiology SUD Notice Number: NOT-DA-20-020 Key Dates Release Date: February 24, 2020 First Available Due Date: June… More | ||
| Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access (X01) | PAR-21-044 | NIDA | The Population Assessment of Tobacco and Health (PATH) Study provides the scientific community with biospecimens (urine, plasma, and serum) and related research data on behaviors, attitudes,… More | ||
| NIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research (K12 Clinical Trial Optional) | PAR-20-249 | NIDA | This funding opportunity announcement (FOA) encourages applications for institutional research career development (K12) programs that propose to support intensive supervised research training and… More | ||
| Multi-Site Studies for System-Level Implementation of Substance Use Prevention and Treatment Services (R34 Clinical Trial Optional) | PAR-21-023 | NIDA | As part of the Collaborative Research on Addiction at NIH (CRAN) initiative, NIDA, NIAAA, and NCI join to issue this FOA. The purpose of this FOA is to support the development and testing of… More | ||
| Providing Research Education Experiences to Enhance Diversity in the Next Generation of Substance Use and Addiction Scientists (R25 Clinical Trials Not Allowed) | PAR-20-236 | NIDA | The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this R25 program is to support educational activities that… More | ||
| Genetic analysis of non-human animal models to understand the genomic architecture of substance use disorders and addictive behaviors (U01 Clinical Trial Not Allowed) | PAR-18-789 | NIDA | The goals of this initiative are to discover allelic variants, genomic alterations, and functional changes associated with addictive behaviors in non-human animals through systems studies that employ… More | ||
| Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional) | PAR-21-183 | NIDA | The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the development of Digital Therapeutics (DTx) to treat Substance Use Disorders (SUDs). Advances in technology offer… More | ||
| Education Activities for Responsible Analyses of Complex, Large-Scale Data (R25- Clinical Trial Not Allowed) | RFA-DA-24-027 | NIDA | This concept proposes to advance methodological rigor in NIDA-relevant research by supporting training on the responsible analyses of complex, large-scale datasets involving brain, behavioral,… More | ||
| High Priority HIV and Substance Use Research (R01 Clinical Trial Optional) | RFA-DA-22-040 | NIDA | The purpose of this Funding Opportunity Announcement (FOA) is to support high priority research at the intersection of HIV and substance use. This FOA invites innovative research projects with the… More | ||
| NIDA Animal Genomics Program (U01 Clinical Trial Not Allowed) | PAR-21-244 | NIDA | The purpose of the NIDA Animal Genetics Program is to identify genetic, genomic, and molecular (epi)genetic variants that underlie: 1. Phenotypes associated with addictive behaviors and/or… More | ||
| Cutting-Edge Basic Research Awards (CEBRA) (R21 Clinical Trial Optional) | PAR-21-208 | NIDA | The National Institute on Drug Abuse (NIDA) Cutting-Edge Basic Research Award (CEBRA) is designed to foster highly innovative or conceptually creative research related to the etiology,… More | ||
| HEAL Initiative: Translating Research to Practice to End the Overdose Crisis (R61/R33 Clinical Trial Optional) | RFA-DA-23-053 | NIDA | This RFA will act as a parent RFA for the HEAL initiative Translation to Practice Team, specifically encouraging translational dissemination and implementation research focused on addressing… More | ||
| HEAL Initiative: Translating Research to Practice to End the Overdose Crisis (R33 Clinical Trial Optional) | RFA-DA-23-054 | NIDA | This RFA will act as a parent RFA for the HEAL initiative Translation to Practice Team, specifically encouraging translational dissemination and implementation research focused on addressing overdose… More | ||
| Academic Research Enhancement Award for Undergraduate-Focused Institutions (R15 Clinical Trial Required) | PAR-21-154 | NIDA | The purpose of this Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions is to support small scale research grants at institutions that do not receive substantial funding… More | ||
| Pilot and Feasibility Studies in Preparation for Substance Use Prevention Trials (R34 Clinical Trial Optional) | PA-21-110 | NIDA | The purpose of this Funding Opportunity Announcement (FOA) is to encourage pilot and/or feasibility research in the following areas: 1) the development and pilot testing of new or adapted… More | ||
| Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R34 - Clinical Trial Optional) | PA-21-180 | NIDA | This Funding Opportunity Announcement (FOA) encourages pilot and preliminary research in preparation for larger-scale services research effectiveness trials. Relevant trials may test a wide range of… More | ||
| Development and Testing of Novel Interventions to improve HIV Prevention, Treatment, and Program Implementation for People Who Use Drugs (R34 Clinical Trial Required) | PA-21-205 | NIDA | This Funding Opportunity Announcement (FOA) encourages formative research, intervention development, and pilot-testing of interventions. Primary scientific areas of focus include the feasibility,… More | ||
| Blueprint Medtech: Small Business Translator (U44 - Clinical Trial Optional) | PAR-21-282 | NIDA | The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from Small Business Concerns (SBCs) to pursue translational activities and limited-size clinical studies to… More | ||
| NIDA Research Education Program for Clinical Researchers and Clinicians (R25 Clinical Trial Not Allowed) | PAR-21-320 | NIDA | The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NIDA R25 program is to support educational activities… More | ||
| Imaging - Science Track Award for Research Transition (I/START) (R03- Clinical Trial Optional) | PAR-21-310 | NIDA | This funding opportunity announcement (FOA) encourages Small Research Grant (R03) applications to facilitate the entry of investigators to the area of neuroimaging, including both new investigators… More | ||
| Notice of Special Interest (NOSI): Using Data to Advance HIV Epidemic Knowledge and Program Planning | NOT-DA-21-007 | NIDA | The purpose of this Notice is to encourage grant applications proposing research that makes use of available, large data sets with the objective of improving HIV epidemic modeling and service… More | ||
| Imaging - Science Track Award for Research Transition (I/START) (R03- Basic Experimental Studies with Humans Required) | PAR-21-309 | NIDA | This funding opportunity announcement (FOA) encourages Small Research Grant (R03) applications to facilitate the entry of investigators to the area of neuroimaging, including both new investigators… More | ||
| AIDS-Science Track Award for Research Transition (R03 Clinical Trial Optional) | PAS-21-270 | NIDA | This funding opportunity announcement (FOA) seeks to facilitate the entry of both newly independent and early career investigators to the area of drug use and use disorder research and HIV/AIDS. This… More | ||
| Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional) | PAR-22-027 | NIDA | This Funding Opportunity Announcement (FOA) will support pilot, feasibility or exploratory research in 5 priority areas in substance use epidemiology and health services, including: 1) responses to… More | ||
| BRAIN Initiative: Theories, Models and Methods for Analysis of Complex Data from the Brain (R01 Clinical Trial Not Allowed) | RFA-DA-23-039 | NIDA | This FOA solicits the development of theories, computational models, and analytical tools to derive understanding of brain function from complex neuroscience data. Proposed projects could develop… More | ||
| Stimulants and HIV: Addressing Contemporary and Recurring Epidemics (R61/R33 - Clinical Trial Required) | RFA-DA-23-008 | NIDA | Stimulant use has been increasing among opioid users since 2016, based on overdose data and this makes control of the opioid epidemic more difficult, as it occurs in addition to the continuing influx… More | ||
| NIDA REI: Racial Equity Visionary Award Program for Research on Substance Use and Racial Equity (DP1 Clinical Trial Optional) | RFA-DA-23-026 | NIDA | This initiative invites applications for DP1 awards to support exceptionally creative early career investigators who propose high-impact projects that lead to advances in equity across populations… More | ||
| NIDA REI: Research at Minority Serving Institutions on Neurocognitive Mechanisms Underlying the Impact of Structural Racism on the Substance Use Trajectory (R61/R33 Clinical Trial Optional) | RFA-DA-23-029 | NIDA | NEPS Concept # 1862 This concept seeks to support exploratory basic research on interpersonal racism and on parsing the complex effects of structural racism into sub-components and their impact… More |
||
| NIDA REI: Addressing Racial Equity in Substance Use and Addiction Outcomes Through Community-Engaged Research (R01 Clinical Trial Optional) | RFA-DA-23-013 | NIDA | NEPS Concept # 1875 This FOA invites R01 applications?to conduct research that will have a major impact in identifying, developing, implementing, or testing strategies to prevent, reduce, or… More |
||
| NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial and/or Ethnic Populations (R01 Clinical Trial Optional) | RFA-DA-23-061 | NIDA | This Funding Opportunity Announcement (FOA) is a part of NIDAs Racial Equity Initiative (REI), a multi-year, multi-pronged effort to eliminate racial inequities in NIDAs workplace, scientific… More | ||
| NIDA REI: Research on Neurocognitive Mechanisms Underlying the Impact of Structural Racism on the Substance Use Trajectory (R61/R33 Clinical Trial Optional) | RFA-DA-23-028 | NIDA | NEPS Concept # 1862 This concept seeks to support exploratory basic research on interpersonal racism and on parsing the complex effects of structural racism into sub-components and their impact… More |
||
| NIDA REI: Racial Equity Visionary Award Program for Research at Minority Serving Institutions on Substance Use and Racial Equity (DP1 Clinical Trial Optional) | RFA-DA-23-031 | NIDA | This initiative invites applications for DP1 awards to support exceptionally creative early career investigators who propose high-impact projects that lead to advances in equity across populations… More | ||
| NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial and/or Ethnic Populations (R34 Clinical Trial Optional) | RFA-DA-23-062 | NIDA | This Funding Opportunity Announcement (FOA) is a part of NIDAs Racial Equity Initiative (REI), a multi-year, multi-pronged effort to eliminate racial inequities in NIDAs workplace, scientific… More | ||
| NIDA REI: Addressing Racial Equity in Substance Use and Addiction Outcomes Through Community-Engaged Research at Minority Serving Institutions (R01 Clinical Trial Optional) | RFA-DA-23-032 | NIDA | NEPS Concept # 1875 This funding opportunity announcement (FOA)?is a part of?NIDAs Racial Equity Initiative.?This?multi-year,?multi-pronged effort?to address ?racial and ethnic inequities in… More |
||
| NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial/Ethnic Populations (R01 Clinical Trial Optional) | RFA-DA-23-023 | NIDA | This Funding Opportunity Announcement (FOA) is a part of NIDAs Racial Equity Initiative (REI), a multi-year, multi-pronged effort to eliminate racial inequities in NIDAs workplace, scientific… More | ||
| Accelerating the Pace of Drug Abuse Research Using Existing Data (R21 Clinical Trial Optional) | RFA-DA-24-037 | NIDA | The purpose of this Funding Opportunity Announcement (FOA) is to invite applications proposing the innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to… More | ||
| Accelerating the Pace of Drug Abuse Research Using Existing Data (R01 Clinical Trial Optional) | RFA-DA-22-037 | NIDA | The purpose of this Funding Opportunity Announcement (FOA) is to invite applications proposing the innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to… More | ||
| Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic (UPS) Opioids (R01 Clinical Trial Not Allowed) | RFA-DA-23-056 | NIDA | This Funding Opportunity Announcement (FOA) will support transformative research to identify and validate mechanisms, signaling pathways, and therapeutic targets, for understanding and reversing the… More | ||
| Notice of Special Interest (NOSI): High-Priority Interest to Enhance Data Science Research Training in Addiction Research | NOT-DA-21-013 | NIDA | Data science is an important cross-cutting research approach in the NIDA Strategic Plan and increasing the capacity of experts in data science for biomedical research of addiction is critical. The… More | ||
| Notice of Special Interest (NOSI): Advancing HIV/AIDS Research through Computational Neuroscience | NOT-DA-21-030 | NIDA | This Notice of Special Interest [NOSI] is to support computational HIV/AIDS research as it relates to NIDAs mission through collaborative research between investigators with experimental expertise… More | ||
| Notice of Special Interest: Advanced Computational Approaches to Elucidate Disease Pathology and Identify Novel Therapeutics for Addiction | NOT-DA-21-004 | NIDA | The purpose of this Notice is to inform potential applicants to the National Institute on Drug Abuse (NIDA) of NIDA's interest in grant applications that will develop or utilize advanced… More | ||
| Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R43/R44 - Clinical Trial Optional) | RFA-DA-23-021 | NIDA | This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) proposing research projects, directed towards… More | ||
| Behavioral and Integrative Treatment Development Program (R34 Clinical Trial Optional) | PAR-22-183 | NIDA | The purpose of this funding opportunity announcement (FOA) is to encourage behavioral intervention development research to test efficacy, conduct clinical trials, examine mechanisms of behavior… More | ||
| Behavioral and Integrative Treatment Development Program (R01 Clinical Trial Optional) | PAR-22-182 | NIDA | The purpose of this funding opportunity announcement (FOA) is to encourage behavioral intervention development research to test efficacy, conduct clinical trials, examine mechanisms of behavior… More | ||
| Functional Validation and/or Characterization of Genes or Variants Implicated in Substance Use Disorders (R21/R33 Clinical Trial Not Allowed) | PAR-23-041 | NIDA | The purpose of this initiative is to support projects which exploit genome or epigenome editing to functionally validate and characterize genes or variants involved in substance use disorder-relevant… More | ||
| Avenir Award Program for Chemistry and Pharmacology of Substance Use Disorders (DP1- Clinical Trial Not Allowed) | RFA-DA-24-007 | NIDA | oThe goal of this FOA is to attract outstanding early-stage investigators to the field of chemistry and pharmacology of substance used disorders. The award will support those in an early stage of… More | ||
| Ex Vivo Models for Studies at the Intersection of HIV and Poly-Substance Use (R01 Clinical Trial Not Allowed) | RFA-DA-24-001 | NIDA | This Funding Opportunity Announcement (FOA) invites grant applications aimed at elucidating neuroimmune and neuronal-glial pathophysiological mechanisms of HIV-associated neurological disorders (HAND… More | ||
| NIDA Avant-Garde Program for HIV and Substance Use Disorder Research (DP1 Clinical Trial Optional) | PAR-23-269 | NIDA | The NIDA Avant-Garde Award Program for HIV/AIDS Research supports individual scientists of exceptional creativity who propose high-impact research that will open new areas of HIV/AIDS research… More | ||
| Avenir Award Program for Research on Substance Use Disorders and HIV (DP2 Clinical Trial Optional) | PAR-23-125 | NIDA | Avenir means future in French, and the Avenir Award Program for Research on Substance Abuse and HIV/AIDS looks toward the future by supporting early stage investigators (ESI) proposing highly… More | ||
| Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional) | PAR-22-202 | NIDA | The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the development of medication for the treatment of Substance Use Disorders (SUDs) by encouraging research applications to… More | ||
| Development of Medications to Prevent and Treat Opioid and/or Stimulant Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional) | PAR-22-200 | NIDA | The purpose of this Funding Opportunity Announcement is to support the discovery and development of medications to prevent and treat opioid and/or psychostimulant use disorders and overdose. … More |
||
| Notice of Special Interest (NOSI): Leveraging Data Science to Bring Actionable Insights for Substance Use Prevention and Treatment | NOT-DA-23-006 | NIDA | The purpose of this NOSI is to develop a portfolio of research projects that use data science such as predictive modeling to provide actionable insights for substance use prevention and treatment and… More | ||
| Notices of Special Interest (NOSI): High Priority Areas in Genetics, Epigenetics, and Developmental Neuroscience Branch in the Division of Neuroscience and Behavior | NOT-DA-23-004 | NIDA | The mission of the Division of Neuroscience and Behavior (DNB) is to discover, facilitate and promote outstanding basic animal and human research aimed at identifying the causes and consequences of… More | ||
| Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional) | PAR-23-021 | NIDA | Avenir means future in French, and this award looks toward the future by supporting early stage investigators proposing highly innovative studies. The award will support those in an early stage of… More | ||
| HEAL Initiative: Career Development Awards in Implementation Science for Substance Use Prevention and Treatment (K01 - Clinical Trial Required) | PAS-22-206 | NIDA | This HEAL FOA provides an opportunity for early career researchers or early career clinicians with foundational backgrounds in addiction to develop expertise in implementation science. Successful… More | ||
| HEAL Initiative: Career Development Awards in Implementation Science for Substance Use Prevention and Treatment (K23 - Clinical Trial Required) | PAS-22-207 | NIDA | This HEAL FOA provides an opportunity for early career researchers or early career clinicians with foundational backgrounds in addiction to develop expertise in implementation science. Successful… More | ||
| NIDA Core "Center of Excellence" Grant Program (P30 Clinical Trial Optional) | PAR-23-049 | NIDA | NIDA Core Center of Excellence Grants (P30) are intended to bring together investigators currently funded by NIH or other Federal or non-Federal sources, to enhance the effectiveness of existing… More | ||
| NIDA Research Center of Excellence Grant Program (P50 Clinical Trial Optional) | PAR-23-076 | NIDA | This Funding Opportunity Announcement (FOA) is to provide support for research Centers that (1) conduct drug abuse and addiction research in any area of NIDAs mission, (2) have outstanding innovative… More | ||
| Notice of Special Interest (NOSI): Pharmacogenomic Approaches to Enhancing HIV and Substance Use Disorder (SUD) Treatment Strategies, A jump into Precision Medicine. | NOT-DA-24-001 | NIDA | Variable responses to ART are due at least in part to human genetic variants that affect drug metabolism, drug disposition, and off-site drug targets. Defining effects of human genetic variants on… More | ||
| Otolaryngology Residency Mentored Research Pathway (R25 Clinical Trial Not Allowed) | RFA-DC-20-002 | NIDCD | The purpose of this program is to recruit and retain outstanding, postdoctoral-level health professionals who have demonstrated potential and interest in pursuing careers as clinician-investigators.… More | ||
| NIDCD Research Opportunities for New Investigators to Promote Workforce Diversity (R01 Clinical Trial Optional) | RFA-DC-23-001 | NIDCD | This Funding Opportunity Announcement (FOA) solicits R01 grant applications that propose independent research projects that are within the scientific mission areas of the National Institute on… More | ||
| NIDCD Cooperative Agreement for Clinical Trials in Communication Disorders (U01 - Clinical Trial Required) | PAR-21-064 | NIDCD | The NIDCD is committed to identifying effective interventions for the treatment or prevention of communication disorders by supporting welldesigned and wellexecuted clinical trials. This funding… More | ||
| NIDCD Early Career Research(ECR) Award (R21 Clinical Trial Optional) | PAR-21-107 | NIDCD | The NIDCD Early Career Research (ECR) Award (R21) is intended to support both basic and clinical research from scientists who are beginning to establish an independent research career. It cannot be… More | ||
| NIDCD Research Career Enhancement Award for Established Investigators (K18 Independent Basic Experimental Studies with Humans Required) | PAR-21-096 | NIDCD | The purpose of the NIDCD Research Career Enhancement Award for Established Investigators (K18) program is to enable established, proven investigators to augment or redirect their research programs… More | ||
| NIDCD Low Risk Clinical Trials in Communication Disorders (R01 Clinical Trial Required) | PAR-21-063 | NIDCD | The NIDCD is committed to identifying effective interventions for the diagnosis, prevention, or treatment of communication disorders by supporting well-designed and well-executed clinical trials.… More | ||
| NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01 Independent Basic Experimental Studies with Humans Required) | PAR-21-087 | NIDCD | The purpose of the NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01) is to support comprehensive and rigorous postdoctoral research and career development… More | ||
| NIDCD Research Career Enhancement Award for Established Investigators (K18 Independent Clinical Trial Not Allowed) | PAR-21-095 | NIDCD | The purpose of the NIDCD Research Career Enhancement Award for Established Investigators (K18) program is to enable established, proven investigators to augment or redirect their research programs… More | ||
| NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01 No Independent Clinical Trials) | PAR-21-086 | NIDCD | The purpose of the NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01) is to support comprehensive and rigorous postdoctoral research and career development… More | ||
| NIDCD Research Dissertation Fellowship for Au.D. Audiologists (F32) | PAR-21-093 | NIDCD | The purpose of the NIDCD Research Dissertation Fellowship for Au.D. Audiologists (F32) program is to support a comprehensive, rigorous biomedical research training, and dissertation research leading… More | ||
| NIDCD Research Career Enhancement Award for Established Investigators (K18 Clinical Trial Required) | PAR-21-094 | NIDCD | The purpose of the NIDCD Research Career Enhancement Award for Established Investigators (K18) program is to enable established, proven investigators to augment or redirect their research programs… More | ||
| NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01 Clinical Trial Required) | PAR-21-085 | NIDCD | The purpose of the NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01) is to support comprehensive and rigorous postdoctoral research and career development… More | ||
| Research Experiences to Enhance Clinician-Scientists' Participation in NIDCDs Research (R25 Clinical Trial Not Allowed) | PAR-21-188 | NIDCD | The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that… More | ||
| Mentoring Networks to Enhance Diversity in NIDCD's Extramural Research Workforce (R25 Clinical Trial Not Allowed) | PAR-21-185 | NIDCD | The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that… More | ||
| NIDCD's Mentoring Networks to Enhance Clinician-Scientists' Participation in Research (R25 Clinical Trial Not Allowed) | PAR-21-187 | NIDCD | The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that… More | ||
| Enhancing NIDCD's Extramural Workforce Diversity through Research Experiences (R25 Clinical Trial Not Allowed) | PAR-21-186 | NIDCD | The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that… More | ||
| NIDCD Research Grants for Translating Basic Research into Clinical Tools (R01 Clinical Trial Optional) | RFA-DC-22-001 | NIDCD | This Funding Opportunity Announcement (FOA) is intended to provide an avenue for basic scientists, clinicians and clinical scientists to jointly initiate and conduct translational research projects… More | ||
| NIDCD Clinical Research Center Grant (P50 Clinical Trial Optional) | PAR-22-025 | NIDCD | The National Institute on Deafness and Other Communication Disorders (NIDCD) invites applications for Clinical Research Center Grants designed to advance the diagnosis, prevention, treatment, and… More | ||
| Advancing HIV/AIDS Research within the Mission of the NIDCD (R01 Clinical Trial Optional) | PAR-23-099 | NIDCD | The purpose of this Funding Opportunity Announcement (FOA) is to stimulate HIV/AIDS research within the scientific mission areas of the National Institute on Deafness and Other Communications… More | ||
| Notice of Special Interest (NOSI): Fundamental Science Research on the Neural Circuits Underlying Sensory Processing | NOT-DC-23-001 | NIDCD | The National Institute on Deafness and Other Communication Disorders (NIDCD) is issuing this Notice to highlight priorities, from its new strategic plan, in basic and mechanistic research on neural… More | ||
| Advancing HIV/AIDS Research within the Mission of the NIDCD (R21 Clinical Trial Optional) | PAR-23-106 | NIDCD | The purpose of this Funding Opportunity Announcement (FOA) is to stimulate HIV/AIDS research within the scientific mission areas of the National Institute on Deafness and Other Communications… More | ||
| Planning for the TMD Collaborative for IMproving PAtient-Centered Translational Research (TMD IMPACT) (R34 Clinical Trial Not Allowed) | RFA-DE-23-014 | NIDCR | To support planning Grant applications that conceptualize the design and implementation of a future national, interdisciplinary, patient-centered research collaborative that will advance… More | ||
| Enabling Technologies to Accelerate Development of Oral Biodevices (R21 Clinical Trial Not Allowed) | PAR-20-232 | NIDCR | This Funding Opportunity Announcement (FOA) invites exploratory/developmental applications that propose transformative engineering solutions to technical challenges associated with meaningful… More | ||
| Enabling Technologies to Accelerate Development of Oral Biodevices (R01 Clinical Trial Not Allowed) | PAR-20-233 | NIDCR | This Funding Opportunity Announcement (FOA) invites applications that propose transformative engineering solutions to technical challenges associated with new development, substantial optimization of… More | ||
| Notice of Special Interest (NOSI) of NIDCR in Supporting Dental, Oral, and Craniofacial Research Using Bioinformatic, Computational, and Data Science Approaches | NOT-DE-20-006 | NIDCR | Notice Special Interest NOSI) NIDCR Supporting Dental, Oral, Craniofacial Research Using Bioinformatic, Computational, Data Science Approaches Notice Number: NOT-DE-20-006 Key Dates Release Date:… More | ||
| National Dental Practice-Based Research Network Clinical Trial or Observational Study Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Optional) | PAR-20-306 | NIDCR | This Funding Opportunity Announcement (FOA) is soliciting applications for clinical trials and large clinical observational studies to be conducted in the National Dental PBRN through a milestone-… More | ||
| NIDCR Dual Degree Dentist Scientist Predoctoral to Postdoctoral Transition Award (F99/K00 Independent Clinical Trial Not Allowed) | PAR-21-108 | NIDCR | The purpose of the NIDCR Dual Degree Dentist Scientist Predoctoral to Postdoctoral Transition Award (F99/K00) is to provide support and mentorship to outstanding students enrolled in integrated dual… More | ||
| NIDCR Small Grant Program for New Investigators (R03 Clinical Trial Not Allowed) | PAR-21-084 | NIDCR | The NIDCR Small Grant Program for New Investigators (R03) supports basic and clinical research conducted by scientists who are in the early stages of establishing an independent research career in… More | ||
| NIDCR Predoctoral to Postdoctoral Transition Award for a Diverse Dental, Oral and Craniofacial Research Workforce (F99/K00 Independent Clinical Trial Not Allowed) | PAR-21-060 | NIDCR | The purpose of the NIDCR Predoctoral to Postdoctoral Transition Award for a Diverse Dental, Oral and Craniofacial Research Workforce (F99/K00) is to support outstanding graduate students from diverse… More | ||
| Continuation or Revision of NIDCR Clinical Trial Implementation Cooperative Agreement (UH3 Clinical Trial Required) | PAR-22-068 | NIDCR | This Funding Opportunity Announcement (FOA) will accept applications for competing renewal or competitive revisions of ongoing clinical trials supported by the National Institute of Dental and… More | ||
| NIDCR Behavioral and Social Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required) | PAR-21-317 | NIDCR | The purpose of this Funding Opportunity Announcement (FOA) is to encourage UG3/UH3 phased cooperative agreement research applications to plan and implement behavioral and social intervention clinical… More | ||
| NIDCR Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required) | PAR-21-160 | NIDCR | The purpose of this Funding Opportunity Announcement (FOA) is to seek UG3/UH3 phased cooperative agreement research applications to plan and implement clinical trials within the mission of NIDCR.… More | ||
| NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22 Clinical Trial Required) | PAR-22-045 | NIDCR | The purpose of the NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22) program is to provide highly qualified dentists in NIH Intramural postdoctoral fellowship… More | ||
| NIDCR Mentored Career Development Award to Promote Diversity (K01 Independent Clinical Trial Not Allowed) | PAR-22-050 | NIDCR | The purpose of the NIDCR Mentored Career Development Award to Promote Diversity in the Dental, Oral and Craniofacial Workforce is to support postdoctoral fellows and early career faculty from diverse… More | ||
| NIDCR Dual Degree Dentist Scientist Pathway to Independence Award (K99/R00 Clinical Trial Not Allowed) | PAR-22-041 | NIDCR | The purpose of the NIDCR Dual Degree Dentist Scientist Pathway to Independence Award (K99/R00) program is to develop and maintain a strong cohort of independent dentist scientists. This program is… More | ||
| NIDCR Mentored Career Development Award to Promote Diversity (K01 Independent Basic Experimental Studies with Humans Required) | PAR-22-052 | NIDCR | The purpose of the NIDCR Mentored Career Development Award to Promote Diversity is to support postdoctoral fellows and early career faculty from diverse backgrounds, including those from groups… More | ||
| NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22 Clinical Trial Not Allowed) | PAR-22-044 | NIDCR | The purpose of the NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22) program is to provide highly qualified dentists in NIH Intramural postdoctoral fellowship… More | ||
| NIDCR Dual Degree Dentist Scientist Pathway to Independence Award (K99/R00 Basic Experimental Studies Involving Humans Required) | PAR-22-043 | NIDCR | The purpose of the NIDCR Dual Degree Dentist Scientist Pathway to Independence Award (K99/R00) program is to develop and maintain a strong cohort of independent dentist scientists. This program is… More | ||
| NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22 Basic Experimental Studies Involving Humans Required) | PAR-22-046 | NIDCR | The purpose of the NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22) program is to provide highly qualified dentists in NIH Intramural postdoctoral fellowship… More | ||
| Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Not Allowed) | PAR-22-060 | NIDCR | The purpose of the Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools is to stimulate basic and clinical research in educational institutions that provide… More | ||
| NIDCR Mentored Career Development Award to Promote Diversity (K01 Clinical Trial Required) | PAR-22-051 | NIDCR | The purpose of the NIDCR Mentored Career Development Award to Promote Diversity is to support postdoctoral fellows and early career faculty from diverse backgrounds, including those from groups… More | ||
| NIDCR Dual Degree Dentist Scientist Pathway to Independence Award (K99/R00 Clinical Trial Required) | PAR-22-042 | NIDCR | The purpose of the NIDCR Dual Degree Dentist Scientist Pathway to Independence Award (K99/R00) program is to develop and maintain a strong cohort of independent dentist scientists. This program is… More | ||
| Short-term Mentored Career Enhancement Award in Dental, Oral, and Craniofacial Research for Mid-Career and Senior Investigators (K18- Independent Clinical Trial Not Allowed) | PAR-22-121 | NIDCR | The purpose of the NIDCR Short-term Mentored Career Enhancement (K18) awards in dental, oral, and craniofacial (DOC) research is to provide mid-career and senior investigators with short-term (2.5… More | ||
| NIDCR Small Research Grants for Oral Health Data Analysis and Statistical Methodology Development (R03 Clinical Trial Not Allowed) | PAR-22-160 | NIDCR | The goal of this funding opportunity announcement is to support meritorious research projects that involve secondary statistical analyses of existing dental, oral or craniofacial database resources,… More | ||
| Human Islet Research Network (HIRN) Pancreas Knowledgebase Program (PanKbase) (U24 - Clinical Trial Not Allowed) | RFA-DK-22-018 | NIDDK | The purpose of this Funding Opportunity Announcement (FOA) is to continue development and expansion of the NIDDK Information Network (dkNET) under the direction of the dkNET Coordinating Unit (dkNET-… More | ||
| NIDDK Information Network Coordinating Unit: dkNET-CU (U24 Clinical Trial Not Allowed) | RFA-DK-22-017 | NIDDK | The purpose of this Funding Opportunity Announcement (FOA) is to continue development and expansion of the NIDDK Information Network (dkNET) under the direction of the dkNET Coordinating Unit (dkNET-… More | ||
| Advancing Research on Mechanisms and Management of Pain for Diseases and Conditions within NIDDK Mission Areas (R01 Clinical Trial Optional) | RFA-DK-23-006 | NIDDK | The impact of pain on patient quality of life for diseases and conditions within the mission of the NIDDK is enormous. Despite prior research efforts, our understanding of the underlying biological… More | ||
| Catalytic Tool and Technology Development in Kidney, Urologic, and Hematologic Diseases (R21 Clinical Trial Not Allowed) | PAR-20-140 | NIDDK | The purpose of this Funding Opportunity Announcement is to promote development of innovative, enabling tools and technologies in the areas of kidney, urologic, and hematologic diseases. | ||
| Limited Competition for the Continuation of the Rare and Atypical Diabetes NeTwork (RADIANT) Specialized Study Centers (U54 - Clinical Trial Not Allowed) | RFA-DK-22-511 | NIDDK | This Funding Opportunity Announcement (FOA) invites applications from the two previously funded Rare and Atypical DIAbetes NeTwork (RADIANT) research centers to further study rare and atypical forms… More | ||
| Silvio O. Conte Digestive Diseases Research Core Centers (P30 Clinical Trial Optional) | RFA-DK-21-026 | NIDDK | This Funding Opportunity Announcement (FOA) invites applications for Silvio O. Conte Digestive Diseases Research Core Centers (DDRCCs). The DDRCCs are part of an integrated program of digestive and… More | ||
| Pilot and Feasibility Studies to Facilitate the Use of Diabetes Self-Management Education and Support to Improve Diabetes Care (R34 Clinical Trial Required) | RFA-DK-20-032 | NIDDK | The purpose of this funding opportunity announcement (FOA) is to test an innovative and pragmatic approach to address barriers to and facilitate greater use of diabetes self-management education and… More | ||
| Notice of Special Interest: Kidney Precision Medicine Technology Development and Translation | NOT-DK-21-007 | NIDDK | This NOSI intends to encourage small businesses to translate kidney precision medicine discoveries and technologies. | ||
| Identification and Characterization of Bioactive Microbial Metabolites for Advancing Research on Microbe-Diet-Host Interactions (R01 Clinical Trial Not Allowed) | PAR-21-253 | NIDDK | The purpose of the Funding Opportunity Announcement is to invite applications to identify and characterizemicrobial metabolites that will establish causal associations between microbial metabolism… More | ||
| Fostering Research With Additional Resources and Development (FORWARD) Urology Centers (P20 Clinical Trial Not Allowed) | RFA-DK-22-027 | NIDDK | The overall goal of the Fostering Research with Additional Resources and Development (FORWARD) Urology Centers program is to foster and expand the urology (excluding cancer) research community. The… More | ||
| Pilot Interventions to Integrate Social Care and Medical Care to Improve Health Equity (R01 Clinical Trial Required) | RFA-DK-22-038 | NIDDK | This NIDDK Funding Opportunity Announcement will support pilot and feasibility trials to test interventions that involve screening for and addressing adverse social determinants of health (SDoH),… More | ||
| Postbaccalaureate Research Education Program in Diabetes, Endocrinology and Metabolic Diseases (R25 Independent Clinical Trial not Allowed) | RFA-DK-22-037 | NIDDK | This Funding Opportunity Announcement (FOA) provides support to eligible, domestic institutions to develop and implement Postbaccalaureate Research Education Programs in Diabetes, Endocrinology and… More | ||
| Collaborative Research Using Biosamples from Type 1 Diabetes Clinical Studies (R01 - Clinical Trial Not Allowed) | RFA-DK-22-021 | NIDDK | This Funding Opportunity Announcement (FOA) invites applications for studies of type 1 diabetes etiology and pathogenesis using data and samples from clinical trials and studies. This opportunity is… More | ||
| Clinical, Behavioral, and Physiological Studies of Open- and Closed-loop Platforms: Toward Personalized, Fully Automated, Accessible Systems (R01 Clinical Trial Required) | RFA-DK-22-020 | NIDDK | The purpose of this fundng opportunity announcemnt (FOA) is to promote clinical research using current and emerging technologies to address barriers that limit progress toward physiological… More | ||
| Ancillary Studies to the NIDDK Inflammatory Bowel Disease Genetics Consortium (R01 Clinical Trial Not Allowed) | RFA-DK-22-023 | NIDDK | The NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC), in collaboration with the International IBD Genetics Consortium, has identified over 250 susceptibility loci for IBD. The IBDGC has… More | ||
| NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Required) | PAR-21-102 | NIDDK | This FOA invites applications for investigator-initiated, high-risk multi-center clinical trials involving m?o?r?e? ?t?h?a?n? ?o?n?e? clinical center. Proposed trials should be hypothesis-driven,… More | ||
| Priority HIV/AIDS Research within the Mission of the NIDDK (R01 Clinical Trial Optional) | PAS-21-031 | NIDDK | This Funding Opportunity Announcement (FOA) seeks to stimulate HIV/AIDS research within the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) that align with the… More | ||
| NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Not Allowed) | PAR-21-103 | NIDDK | This FOA invites applications for investigator-initiated, high-risk multi-center observational studies involving more than one clinical center. Proposed studies should be hypothesis-driven and focus… More | ||
| Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogenesis Within the Mission of the NIDDK (R21 Clinical Trial Not Allowed) | PAR-21-062 | NIDDK | This Funding Opportunity Announcement (FOA) invites applications for innovative basic and translational pilot research projects within the mission of the NIDDK that are aligned with NIH HIV/AIDS… More | ||
| Limited Competition: NIDDK Program Projects (P01 Clinical Trial Optional) | PAR-23-121 | NIDDK | New biologic knowledge will come from both sole investigators following their vision and from teams of scientists sharing their expertise. Some complex biomedical problems require a multidisciplinary… More | ||
| NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34 Clinical Trial Optional) | PAR-21-101 | NIDDK | NIDDK supports investigator-initiated, high-risk multi-center (more than one center) clinical studies through a two-part process that may include an implementation planning cooperative agreement (U34… More | ||
| Pilot and Feasibility Trials on the Integration of Social and Medical Care for Type 1 Diabetes Mellitus (R01 Clinical Trial Required) | RFA-DK-22-028 | NIDDK | The purpose of this NIDDK Funding Opportunity Announcement (FOA) is to support pilot and feasibility trials to test pragmatic interventions that include screening for adverse social determinants of… More | ||
| New Directions in Hematology Research (SHINE-II) (R01 Clinical Trial Optional) | PAS-21-150 | NIDDK | This Funding Opportunity Announcement (FOA) seeks innovative grant applications in nonmalignant hematology research that will steer the field in new directions. Applications to this FOA should… More | ||
| Small Grants for New Investigators to Promote Diversity in Health-Related Research (R21 Clinical Trial Optional) | PAR-21-313 | NIDDK | The purpose of this Funding Opportunity Announcement (FOA) is to provide support for new investigators from diverse backgrounds, including from groups nationally underrepresented in biomedical… More | ||
| Time-Sensitive Obesity Policy and Program Evaluation (R01 Clinical Trial Not Allowed) | PAR-21-305 | NIDDK | This Funding Opportunity Announcement (FOA) establishes an accelerated review/award process to support time-sensitive research to evaluate a new policy or program that is likely to influence obesity… More | ||
| High Impact, Interdisciplinary Science in NIDDK Research Areas (RC2 Clinical Trial Optional) | PAR-22-069 | NIDDK | The purpose of the High Impact, Interdisciplinary Science grants program is to support high impact ideas that may lay the foundation for new fields of investigation within the mission of NIDDK. The… More | ||
| Early-Stage Preclinical Validation of Therapeutic Leads for Diseases of Interest to the NIDDK (R01 Clinical Trial Not Allowed) | PAR-22-111 | NIDDK | The goal of this Funding Opportunity Announcement (FOA) is to support translational research that provides strong justification for later-phase therapeutics discovery and development efforts in… More | ||
| Stimulating Hematology Investigation: New Endeavors (SHINE) (R01 Clinical Trial Not Allowed) | PAS-22-096 | NIDDK | The Stimulating Hematology Investigation: New Endeavors (SHINE) program is intended to promote innovative, high-quality nonmalignant hematology research relevant to the missions of the National… More | ||
| KUH Predoctoral to Postdoctoral Fellow Transition Award (F99/K00 - Independent Clinical Trial Not Allowed) | RFA-DK-21-033 | NIDDK | The purpose of the Kidney, Urology or Hematology (KUH) Predoctoral to Postdoctoral Fellow Transition Awards (F99/K00) is to recruit exceptional graduate students from diverse research fields to… More | ||
| Catalyst Award for Early-Stage Investigators (ESIs) Pursuing Research on HIV Comorbidities, Coinfections, and Complications (DP1- Clinical Trial Optional) | PAR-23-024 | NIDDK | This Funding Opportunity Announcement (FOA) supports research from creative early stage investigators who propose highly innovative, pioneering studies with potential to open new areas of HIV/AIDS… More | ||
| Stimulating Urology Interdisciplinary Team Opportunity Research (SUITOR) (R01 Clinical Trial Optional) | PAS-22-074 | NIDDK | The Stimulating Urology Interdisciplinary Team Opportunity Research (SUITOR) program is intended to promote innovative, high quality, interdisciplinary research relevant to the mission of the… More | ||
| NIDDK Central Repository Non-renewable Sample Access (X01 Clinical Trial Not Allowed) | PAR-22-171 | NIDDK | The NIDDK Central Repositories house valuable biological samples and data from numerous major clinical studies. This initiative allows investigators to apply for access to non-renewable samples from… More | ||
| Limited Competition: Small Grant Program for NIDDK K01/K08/K23/K25 Recipients (R03 Clinical Trial Optional) | PAR-22-129 | NIDDK | The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) announces a program that provides NIDDK-supported K01, K08, K23, and K25 recipients the opportunity to apply for Small… More | ||
| Small R01s for Clinical Trials Targeting Diseases within the Mission of NIDDK (R01 Clinical Trial Required) | PAS-23-086 | NIDDK | This Funding Opportunity Announcement encourages the submission ofpilot and feasibilityclinical trialsconducted in humans that will lay the foundation for larger clinical trials related to the… More | ||
| Accelerating Data and Metadata Standards in the Environmental Health Sciences (R24 Clinical Trial Not Allowed) | RFA-ES-23-002 | NIEHS | The purpose of this Funding Opportunity Announcement (FOA) is to support resource projects to enable Environmental Health Sciences (EHS) communities to openly develop, extend, adapt, or refine data… More | ||
| Novel Approaches for Developmental Neurotoxicity Testing (R43/R44 Clinical Trial Not Allowed) | RFA-ES-23-008 | NIEHS | This Notice of Funding Opportunity (NOFO) supports Phase I (R43), Phase II (R44), Direct to Phase II (R44), and Fast Track (R44) Small Business Innovative Research (SBIR) grant applications from… More | ||
| SBIR E-Learning for HAZMAT and Emergency Response (R43/R44 Clinical Trial Not Allowed) | RFA-ES-23-005 | NIEHS | This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to further the development of… More | ||
| CCRP Initiative: Chemical Threat Agent-induced Pulmonary and Ocular Pathophysiological Mechanisms (R01 Clinical Trial Not Allowed) | RFA-ES-21-006 | NIEHS | The purpose of this Funding Opportunity Announcement (FOA) is to support research seeking to understand mechanisms of chemical toxicity and to identify potential molecular/genetic targets that reduce… More | ||
| Exploratory Grants for Climate Change and Health Research Center Development (P20 Clinical Trial Optional) | RFA-ES-23-007 | NIEHS | The purpose of this Funding Opportunity Announcement (FOA) is to solicit P20 planning grant applications for Climate Change and Health Research Centers (CCHRCs). This program will support the… More | ||
| Virtual Consortium for Translational/Transdisciplinary Environmental Research (ViCTER) (R01 Clinical Trial Optional) | RFA-ES-21-007 | NIEHS | The purpose of the ViCTER program is to use the R01 mechanism to foster and promote early-stage transdisciplinary collaborations and/or translational research efforts to address fundamental research… More | ||
| Maintaining and Enriching Environmental Epidemiology Cohorts to Support Scientific and Workforce Diversity (U24 Clinical Trial Not Allowed) | RFA-ES-23-003 | NIEHS | The purpose of this Funding Opportunity Announcement (FOA) is to solicit grant applications that propose to: (1) support the maintenance and resource infrastructure enrichment for existing… More | ||
| Environmental Health Sciences Core Centers (EHSCC) (P30 Clinical Trial Optional) | RFA-ES-22-010 | NIEHS | This Funding Opportunity Announcement (FOA) invites grant applications for Environmental Health Sciences Core Centers (EHS CC). As intellectual hubs for environmental health research, the EHS CC is… More | ||
| Transition to Independent Environmental Health Research (TIEHR) Career Award (K01 Independent Basic Experimental Studies with Humans Required) | PAR-21-170 | NIEHS | The Transition to Independent Environmental Health (TIEHR) Career Award is a 3-year bridge scholar development program for newly independent faculty who intend to pursue research careers in… More | ||
| Transition to Independent Environmental Health Research (TIEHR) Career Award (K01 Clinical Trial Required) | PAR-21-171 | NIEHS | The Transition to Independent Environmental Health (TIEHR) Career Award is a 3-year bridge scholar development program for newly independent faculty who intend to pursue research careers in… More | ||
| Transition to Independent Environmental Health Research (TIEHR) Career Award (K01 Clinical Trial Not Allowed) | PAR-21-172 | NIEHS | The Transition to Independent Environmental Health (TIEHR) Career Award is a 3-year bridge scholar development program for newly independent faculty who intend to pursue research careers in… More | ||
| Research to Action: Assessing and Addressing Community Exposures to Environmental Contaminants (R01 Clinical Trial Optional) | PAR-22-210 | NIEHS | This Funding Opportunity Announcement encourages applications using community-engaged research methods to investigate the potential health risks of environmental exposures of concern to the community… More | ||
| Time-Sensitive Research Opportunities in Environmental Health Sciences (R21 Clinical Trial Not Allowed) | RFA-ES-23-004 | NIEHS | This funding opportunity announcement (FOA) is intended to support novel environmental health research in which an unpredictable event or policy change provides a limited window of opportunity to… More | ||
| Biomedical Data Repository (U24 - Clinical Trials Not Allowed) | PAR-23-079 | NIGMS | This funding opportunity announcement is designed to support biomedical data repositories. Biomedical data repositories under this announcement should have the primary function to ingest, archive,… More | ||
| Biomedical Knowledgebase (U24 - Clinical Trials Not Allowed) | PAR-23-078 | NIGMS | This funding opportunity announcement is designed to support biomedical knowledgebases. Biomedical knowledgebases under this announcement should have the primary function to extract, accumulate,… More | ||
| National Institute of General Medical Sciences Institutional Predoctoral Research Training Grant (T32 - Clinical Trial Not Allowed) | PAR-20-213 | NIGMS | The goal of the National Institute of General Medical Sciences (NIGMS) Ruth L. Kirschstein National Research Service Award (NRSA) Predoctoral Institutional Research Training Grant (T32) program is to… More | ||
| Maximizing Access to Research Careers (T34 - Clinical Trial Not Allowed) | PAR-21-147 | NIGMS | The goal of the Maximizing Access to Research Careers (MARC) program is to develop a diverse pool of undergraduates who complete their baccalaureate degree, and transition into and complete… More | ||
| Undergraduate Research Training Initiative for Student Enhancement (U-RISE) (T34 - Clinical Trial Not Allowed) | PAR-21-146 | NIGMS | The goal of the Undergraduate Research Training Initiative for Student Enhancement (U-RISE) program is to develop a diverse pool of undergraduates who complete their baccalaureate degree, and… More | ||
| Notice of Special Interest (NOSI): Administrative Supplements for Equipment Purchases for Select NIGMS-Funded Awards | NOT-GM-22-017 | NIGMS | The National Institute of General Medical Sciences (NIGMS) announces the availability of funds for administrative supplements to NIGMS-funded R01, R15, R16, R35 and R37 research projects and to… More | ||
| Coordination Center for the Models of Infectious Disease Agent Study (MIDAS) Program (R24 Clinical Trial Not Allowed) | PAR-23-129 | NIGMS | The Coordination Center for the Models of Infectious Disease Agent Study (MIDAS) program will advance infectious disease modeling science by serving as a hub for collaboration and dissemination of… More | ||
| Modules for Enhancing Biomedical Research Workforce Training (R25 Clinical Trial Not Allowed) | PAR-20-296 | NIGMS | The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that… More | ||
| Support for Research Excellence (SuRE) Award (R16 Clinical Trial Not Allowed) | PAR-21-169 | NIGMS | SuRE is a research capacity building program designed to develop and sustain research excellence in U.S. higher education institutions that receive limited NIH research support and serve students… More | ||
| Notice of Special Interest: NIGMS Priorities for Small Business Development of Sepsis Diagnostics and Therapeutics | NOT-GM-20-028 | NIGMS | Notice Special Interest: NIGMS Priorities Small Business Development Sepsis Diagnostics Therapeutics Notice Number: NOT-GM-20-028 Key Dates Release Date: June 2, 2020 First Available Due Date:… More | ||
| National Institute of General Medical Sciences (NIGMS) Bridges to the Doctorate (T32) | PAR-21-198 | NIGMS | The goal of the Bridges to the Doctorate Research Training program is to develop a diverse pool of scientists earning a Ph.D., who have the skills to successfully transition into careers in the… More | ||
| Research on Interventions that Promote the Careers of Individuals in the Biomedical Research Enterprise (R01 Clinical Trial Not Allowed) | PAR-21-269 | NIGMS | This Funding Opportunity Announcement (FOA) encourages solicits applications that propose research designed to test training, mentoring, and networking interventions intended to enhance research-… More | ||
| Innovative Programs to Enhance Research Training (IPERT) (R25 Independent Clinical Trial Not Allowed) | PAR-21-196 | NIGMS | The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NIGMS R25 program is to support educational activities… More | ||
| Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Institutionally-Focused Research Education Award to Promote Diversity (UE5 - Clinical Trial Not Allowed) | PAR-21-277 | NIGMS | The NIH Research Education Program (UE5) supports research education activities in the mission areas of the NIH. The over-arching goal of the MOSAIC UE5 program is to support educational activities… More | ||
| Support for Research Excellence First Independent Research (SuRE-First) Award (R16 - Clinical Trial Not Allowed) | PAR-21-173 | NIGMS | SuRE is a research capacity building program designed to develop and sustain research excellence in U.S. higher education institutions that receive limited NIH research support and serve students… More | ||
| Medical Scientist Training Program (T32) | PAR-21-189 | NIGMS | The goal of the Medical Scientist Training Program (MSTP) is to develop a diverse pool of highly trained physician-scientist leaders available to meet the needs of the Nations biomedical research… More | ||
| Academic Research Enhancement Award for Undergraduate-Focused Institutions (R15 Clinical Trial Not Allowed) | PAR-21-155 | NIGMS | The purpose of this Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions is to support small scale research grants at institutions that do not receive substantial funding… More | ||
| NIGMS National and Regional Resources (R24 - Clinical Trial Not Allowed) | PAR-22-065 | NIGMS | This Funding Opportunity Announcement (FOA) encourages applications for support of national or regional resources that will provide access to state-of-the-art facilities, equipment, technologies,… More | ||
| National Centers for Cryoelectron Microscopy (R24 Clinical Trial Not Allowed) | PAR-23-118 | NIGMS | This initiative will support national service centers for molecular structure determination by high resolution cryoelectron microscopy (cryoEM). The centers will provide access to state-of-the-art… More | ||
| Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Not Allowed) | PAR-21-271 | NIGMS | The purpose of the MOSAIC Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to support a cohort of early career, independent investigators from diverse backgrounds… More | ||
| National Institute of General Medical Sciences (NIGMS) Bridges to the Baccalaureate Research Training Program (T34) | PAR-22-125 | NIGMS | The goal of the Bridges to the Baccalaureate Research Training Program is to provide structured activities to prepare a diverse cohort of research-oriented students to transfer from associate degree-… More | ||
| Institutional Research and Academic Career Development Awards (IRACDA) (K12 - Independent Clinical Trial Not Allowed) | PAR-22-212 | NIGMS | The Institutional Research and Academic Career Development Award (IRACDA) Program provides support for a mentored postdoctoral research experience at a research-intensive institution combined with an… More | ||
| Postdoctoral Research Associate Training (PRAT) Program (Fi2) | PAR-22-191 | NIGMS | The NIGMS Postdoctoral Research Associate Training (PRAT) Programs overarching goal is to provide high quality postdoctoral research training in the basic biomedical sciences to a diverse group of… More | ||
| Limited Competition: NIGMS Mature Synchrotron Resources for Structural Biology (P30 - Clinical Trial Not Allowed) | PAR-22-166 | NIGMS | This Funding Opportunity Announcement (FOA) encourages applications for support of mature structural biology resources at synchrotron facilities. Mature refers to the techniques made available at… More | ||
| Notice of Special Interest (NOSI): Inclusion of Economic Factors and Outcomes in Infectious Disease Modeling Studies | NOT-GM-22-021 | NIGMS | The National Institute of General Medical Sciences (NIGMS) is issuing this Notice to highlight interest in receiving grant applications focused on infectious disease modeling research that… More | ||
| Leading Equity and Diversity in the Medical Scientist Training Program (LEAD MSTP)(T32) | PAR-23-030 | NIGMS | The goal of the Leading Equity and Diversity in the Medical Scientist Training Program (LEAD MSTP) is to develop a diverse pool of highly trained clinician-scientist leaders available to meet the… More | ||
| Centers of Biomedical Research Excellence (COBRE) Phase 1 (P20 - Clinical Trial Optional) | PAR-22-250 | NIGMS | The National Institute of General Medical Sciences (NIGMS) invites applications for renewal of eligible Centers of Biomedical Research Excellence (COBRE) grants. The objective of the COBRE initiative… More | ||
| Postbaccalaureate Research Education Program (PREP)(R25 - Independent Clinical Trial Not Allowed) | PAR-22-220 | NIGMS | This funding opportunity announcement (FOA) provides support to eligible, domestic institutions to develop and implement effective, evidence-informed approaches to biomedical research education and… More | ||
| Technology Development Research for Establishing Feasibility and Proof of Concept (R21 - Clinical Trial Not Allowed) | PAR-22-126 | NIGMS | This initiative will support exploratory research leading to the development of innovative technologies for biomedical research. The program will recognize and reward high risk approaches with… More | ||
| Focused Technology Research and Development (R01 Clinical Trial Not Allowed) | PAR-22-127 | NIGMS | This initiative will support projects that focus solely on development of technologies with the potential to enable acquisition of basic biomedical knowledge. Projects should be justified in terms of… More | ||
| Maximizing Investigators' Research Award (R35 - Clinical Trial Optional) | PAR-22-180 | NIGMS | The Maximizing Investigators' Research Award (MIRA) provides support for the program of research in an investigator's laboratory that is within the mission of NIGMS. The goal of MIRA is to… More | ||
| IDeA Networks of Biomedical Research Excellence (INBRE) (P20 Clinical Trial Optional) | PAR-23-100 | NIGMS | The National Institute of General Medical Sciences (NIGMS) invites applications for Institutional Development Award (IDeA) Networks of Biomedical Research Excellence (INBRE) awards from investigators… More | ||
| Limited Competition: Renewal of Centers of Biomedical Research Excellence (COBRE) (Phase 2) (P20 - Clinical Trial Optional) | PAR-23-063 | NIGMS | The Centers of Biomedical Research Excellence (COBRE) program supports the establishment and development of innovative biomedical and behavioral research centers at Institutional Development Award (… More | ||
| Instrumentation Grant Program for Resource-Limited Institutions (S10 - Clinical Trial Not Allowed) | PAR-23-138 | NIGMS | The Instrumentation Grant Program for Resource-Limited Institutions supports the purchase of state-of-the-art scientific instruments to enhance the research and educational missions of resource-… More | ||
| Biomedical Technology Optimization and Dissemination Center (BTOD)(RM1-Clinical Trial Not Allowed) | PAR-23-110 | NIGMS | This Funding Opportunity Announcement (FOA) encourages applications for NIGMS Biomedical Technology Optimization and Dissemination (BTOD) Centers to support late-stage technology optimization and… More | ||
| Collaborative Program Grant for Multidisciplinary Teams (RM1 - Clinical Trial Optional) | PAR-23-077 | NIGMS | This funding opportunity announcement (FOA) is designed to support highly integrated research teams of three to six PD/PIs to address ambitious and challenging research questions that are important… More | ||
| Research With Activities Related to Diversity (ReWARD) (R01 Clinical Trial Optional) | PAR-23-122 | NIGMS | The NIH ?Research With Activities Related to Diversity (ReWARD) Program's overarching goal is to enhance the breadth and geographical location of research and research-related activities… More | ||
| SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance (SB1, Clinical Trial Not Allowed) | PAR-20-128 | NIH | The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from small business concerns (SBCs) to the newly re-authorized Commercialization Readiness Pilot (CRP) program… More | ||
| SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1 Clinical Trial Required) | PAR-20-130 | NIH | The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from small business concerns (SBCs) to the newly re-authorized Commercialization Readiness Pilot (CRP) program… More | ||
| SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1, Clinical Trial Not Allowed) | PAR-20-129 | NIH | The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from small business concerns (SBCs) to the newly re-authorized Commercialization Readiness Pilot (CRP) program… More | ||
| Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Required) | PA-20-206 | NIH | The purpose of the NIH Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment… More | ||
| Mentored Research Scientist Development Award (Parent K01 Independent Basic Experimental Studies with Humans Required) | PA-20-191 | NIH | The purpose of the NIH Mentored Research Scientist Development Award (K01) is to provide support and protected time (three to five years) for an intensive, supervised career development experience in… More | ||
| NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed) | PA-20-185 | NIH | The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). The proposed project must be… More | ||
| Mentored Quantitative Research Development Award (Parent K25 Independent Basic Experimental Studies with Humans Required) | PA-20-198 | NIH | The purpose of the Mentored Quantitative Research Career Development Award (K25) is to attract to NIH-relevant research those investigators whose quantitative science and engineering research has… More | ||
| Independent Scientist Award (Parent K02 - Independent Clinical Trial Not Allowed) | PA-20-174 | NIH | The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their… More | ||
| NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed) | PA-20-200 | NIH | The NIH Small Research Grant Program supports small research projects that can be carried out in a short period of time with limited resources. This program supports different types of projects… More | ||
| Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Required) | PA-20-193 | NIH | The purpose of the NIH Midcareer Investigator Award in Patient-Oriented Research (K24) is to provide support to mid-career health-professional doctorates for protected time to devote to patient-… More | ||
| Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Required) | PA-20-202 | NIH | The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the… More | ||
| NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required) | PA-20-196 | NIH | The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve… More | ||
| NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Not Allowed) | PA-20-188 | NIH | The purpose of the NIH Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented, NIH-supported, independent investigators. This program is… More | ||
| Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial Not Allowed) | PA-20-199 | NIH | The purpose of the Mentored Quantitative Research Career Development Award (K25) is to attract to NIH-relevant research those investigators whose quantitative science and engineering research has… More | ||
| Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Not Allowed) | PA-20-205 | NIH | The purpose of the NIH Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment… More | ||
| Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Not Allowed) | PA-20-190 | NIH | The purpose of the NIH Mentored Research Scientist Development Award (K01) is to provide support and protected time (three to five years) for an intensive, supervised career development experience in… More | ||
| Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required) | PA-20-184 | NIH | The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). This Parent Funding… More |
||
| Independent Scientist Award (Parent K02 Independent Basic Experimental Studies with Humans Required) | PA-20-173 | NIH | The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their… More | ||
| NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed) | PA-20-195 | NIH | The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve… More | ||
| Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Not Allowed) | PA-20-186 | NIH | The purpose of the NIH Midcareer Investigator Award in Patient-Oriented Research (K24) is to provide support to mid-career health-professional doctorates for protected time to devote to patient-… More | ||
| Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Basic Experimental Studies with Humans Required) | PA-20-201 | NIH | The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the… More | ||
| Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Required) | PA-20-176 | NIH | The purpose of the NIH Mentored Research Scientist Development Award (K01) is to provide support and protected time (three to five years) for an intensive, supervised career development experience in… More | ||
| NIH Pathway to Independence Award (Parent K99/R00 Independent Basic Experimental Studies with Humans Required) | PA-20-189 | NIH | The purpose of the NIH Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented, NIH-supported, independent investigators. This program is… More | ||
| Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial Required) | PA-20-197 | NIH | The purpose of the Mentored Quantitative Research Career Development Award (K25) is to attract to NIH-relevant research those investigators whose quantitative science and engineering research has… More | ||
| Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Basic Experimental Studies with Humans Required) | PA-20-204 | NIH | The purpose of the NIH Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment… More | ||
| Midcareer Investigator Award in Patient-Oriented Research (Parent K24 - Independent Basic Experimental Studies with Humans Required) | PA-20-192 | NIH | The purpose of the NIH Midcareer Investigator Award in Patient-Oriented Research (K24) is to provide support to mid-career health-professional doctorates for protected time to devote to patient-… More | ||
| Research Project Grant (Parent R01 Clinical Trial Required) | PA-20-183 | NIH | The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). This Parent Funding… More | ||
| Independent Scientist Award (Parent K02 - Independent Clinical Trial Required) | PA-20-171 | NIH | The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their… More | ||
| Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Not Allowed) | PA-20-203 | NIH | The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the… More | ||
| NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required) | PA-20-194 | NIH | The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve… More | ||
| NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Required) | PA-20-187 | NIH | The purpose of the NIH Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented, NIH-supported, independent investigators. This program is… More | ||
| Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional) | PA-20-135 | NIH | The National Institutes of Health (NIH) hereby notify the applicant community that funds may be available for applications based on a presidentially declared disaster under the Stafford Act, a public… More | ||
| Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (Parent F32) | PA-21-048 | NIH | The purpose of the Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (Parent F32) is to support research training of highly promising postdoctoral… More | ||
| Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research (Parent F31-Diversity) | PA-21-052 | NIH | The purpose of this Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research award is to enhance the diversity of… More | ||
| Ruth L. Kirschstein National Research Service Award (NRSA) Individual Senior Fellowship (Parent F33) | PA-21-047 | NIH | The National Institutes of Health (NIH) awards senior individual research training fellowships to experienced scientists who wish to make major changes in the direction of their research careers or… More | ||
| Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellowship for Students at Institutions with NIH-Funded Institutional Predoctoral Dual-Degree Training Programs (Parent F30) | PA-21-049 | NIH | This Funding Opportunity Announcement (FOA) will support students at institutions with NIH-funded institutional predoctoral dual-degree training programs. The purpose of the Kirschstein-NRSA, dual-… More | ||
| Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship (Parent F31) | PA-21-051 | NIH | The purpose of the Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship (Parent F31) award is to enable promising predoctoral students to obtain individualized… More | ||
| Limited Competition: Lasker Clinical Research Scholars Transition Award (R00 Clinical Trial Optional) | PAR-20-315 | NIH | The Lasker Clinical Research Scholars Program supports research activities during the early stage careers of independent clinical researchers. This FOA offers the opportunity for current Lasker… More | ||
| Notice of Special Interest (NOSI): Use of Digital Technology and Mobile Health (mHealth) to Improve Diagnosis, Assessments, Interventions, Management and Outcomes for Individuals with Down Syndrome Across the Lifespan (R21 Clinical Trial Not Allowed) | NOT-OD-21-092 | NIH | This Notice invites applications specifically aimed at developing or building upon existing technological tools to improve diagnosis, assessments, interventions, management, and outcomes for infants… More | ||
| Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellowship for Students at Institutions Without NIH-Funded Institutional Predoctoral Dual-Degree Training Programs (Parent F30) | PA-21-050 | NIH | This Funding Opportunity Announcement (FOA) will support students at institutions without NIH-funded institutional predoctoral dual-degree training programs. The purpose of the Kirschstein-NRSA, dual… More | ||
| Stephen I. Katz Early Stage Investigator Research Project Grant (R01 Basic Experimental Studies with Humans Required) | PAR-21-039 | NIH | The Stephen I. Katz Early Stage Investigator Research Project Grant supports an innovative project that represents a change in research direction for an early stage investigator (ESI) and for which… More | ||
| Stephen I. Katz Early Stage Investigator Research Project Grant (R01 Clinical Trial Not Allowed) | PAR-21-038 | NIH | The Stephen I. Katz Early Stage Investigator Research Project Grant supports an innovative project that represents a change in research direction for an early stage investigator (ESI) and for which… More | ||
| NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed) | PA-21-151 | NIH | The purpose of the NIH Research Conference Grant (R13) is to support high quality conferences that are relevant to the public health and to the scientific mission of the participating Institutes and… More | ||
| Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional) | PAR-20-159 | NIMH | The goal of this Funding Opportunity Announcement (FOA) is to encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons… More | ||
| HIV Infection of the Central Nervous System (R01 Clinical Trial Not Allowed) | PA-20-149 | NIMH | The goals of this Funding Opportunity Announcement (FOA) are to stimulate further research on delineating the pathophysiology of HIV-1 associated CNS disease in the setting of chronic viral… More | ||
| Notice of Special Interest: Stigma or Other Social Determinants of Health (SDOH) in HIV Prevention and Treatment | NOT-MH-20-020 | NIMH | Notice Special Interest: Stigma Other Social Determinants Health SDOH) HIV Prevention Treatment Notice Number: NOT-MH-20-020 Key Dates Release Date: March 30, 2020 First Available Due Date: 07, 2020… More | ||
| Eradication of HIV-1 from Central Nervous system Reservoirs (R01 Clinical Trial Not Allowed) | PA-20-151 | NIMH | This Funding Opportunity Announcement (FOA) invites research grant applications studying mechanisms of HIV-1 persistence and eradication strategies specifically focused on the central nervous system… More | ||
| Notice of Special Interest (NOSI): Strengthening the HIV Care Continuum | NOT-MH-20-023 | NIMH | Notice Special Interest NOSI): Strengthening HIV Care Continuum Notice Number: NOT-MH-20-023 Key Dates Release Date: March 30, 2020 First Available Due Date: 07, 2020 Expiration Date: 08, 2023… More | ||
| Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R01 Clinical Trial Optional) | PAR-20-157 | NIMH | The goal of this Funding Opportunity Announcement (FOA) is to encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons… More | ||
| Advanced Laboratories for Accelerating the Reach and Impact of Treatments for Youth and Adults with Mental Illness (ALACRITY) Research Centers (P50 Clinical Trial Optional) | PAR-20-293 | NIMH | This Funding Opportunity Announcement (FOA) invites applications for centers to support transdisciplinary teams of clinical and mental health services researchers, behavioral scientists, social… More | ||
| Understanding Suicide Risk and Protective Factors among Black Youth (R21 Clinical Trial Not Allowed) | RFA-MH-22-141 | NIMH | Proposed as a priority under the Suicide Prevention Transformational Project Strategic Plan, this funding opportunity is aligned with NIMHs commitment to support research that builds on existing… More | ||
| Understanding Suicide Risk and Protective Factors among Black Youth (R01 Clinical Trial Not Allowed) | RFA-MH-22-140 | NIMH | Proposed as a priority under the Suicide Prevention Transformational Project Strategic Plan, this funding opportunity is aligned with NIMHs commitment to support research that builds on existing… More | ||
| Effectiveness and Implementation Research for Post-Acute Interventions to Optimize Long-Term Mental Health Outcomes in Low- and Middle-Income Countries (R34 Clinical Trial Optional) | RFA-MH-23-140 | NIMH | This FOA seeks research applications for effectiveness and implementation science on the post-acute (long-term or chronic) management of mental health conditions. This funding opportunity aims to… More | ||
| BRAIN Initiative: Data Archives for the BRAIN Initiative (R24 Clinical Trial Optional) | RFA-MH-20-600 | NIMH | This Funding Opportunity Announcement (FOA) solicits applications to develop web-accessible data archives to capture, store, and curate data related to BRAIN Initiative activities. The data archives… More | ||
| Cellular and Molecular Biology of Complex Brain Disorders (R21 Clinical Trial Not Allowed) | PAR-20-264 | NIMH | This Funding Opportunity Announcement (FOA) encourages research on the biology of high confidence risk factors associated with complex brain disorders, with a focus on the intracellular,… More | ||
| Behavioral Tasks Targeting Brain Systems Relevant to Anhedonia (R01 Basic Experimental Studies with Humans Required) | PAR-20-235 | NIMH | This Funding Opportunity Announcement (FOA) encourages research to develop task-based behavioral measures that are shown to engage brain systems relevant to anhedonia using neuroimaging or other… More | ||
| Cellular and Molecular Biology of Complex Brain Disorders (R01 Clinical Trial Not Allowed) | PAR-20-263 | NIMH | This Funding Opportunity Announcement (FOA) encourages research on the biology of high confidence risk factors associated with complex brain disorders, with a focus on the intracellular,… More | ||
| Notice of Special Interest to Highlight High Priority Opportunities for Intervention Development Research in Geriatric Mental Health | NOT-MH-20-027 | NIMH | Notice Special Interest Highlight High Priority Opportunities Intervention Development Research Geriatric Mental Health Notice Number: NOT-MH-20-027 Key Dates Release Date: March 19, 2020 First… More | ||
| Developmental AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optional) | PAR-20-307 | NIMH | The National Institute of Mental Health (NIMH) Division of AIDS Research (DAR) encourages applications for Center Core grants (P30) to support HIV/AIDS Research Centers (ARC). The ARC is intended to… More | ||
| AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optional) | PAR-20-308 | NIMH | The National Institute of Mental Health (NIMH) Division of AIDS Research (DAR) encourages applications for Center Core grants (P30) to support HIV/AIDS Research Centers (ARC). The ARC is intended to… More | ||
| BRAIN Initiative: Development and Validation of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in the Brain (R01 Clinical Trial Not Allowed) | RFA-MH-21-175 | NIMH | This is a reissue of RFA-MH-19-136. The purpose of this Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is to encourage applications that will develop and validate… More | ||
| Using Secondary Data Analysis to Determine Whether Preventive Interventions Implemented Earlier in Life Reduce Suicide Risk (U01 Clinical Trial Not Allowed) | RFA-MH-23-275 | NIMH | The purpose of this funding opportunity announcement (FOA) is to encourage research to integrate/harmonize existing large prevention trial data sets implemented earlier in life to examine whether… More | ||
| BRAIN Initiative: Research on the Ethical Implications of Advancements in Neurotechnology and Brain Science (R01 Clinical Trial Optional) | RFA-MH-21-205 | NIMH | Reissue of RFA-MH-19-400. This funding opportunity announcement (FOA), in support of the NIH Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative, is one of several FOAs… More | ||
| BRAIN Initiative: Reagent Resources for Brain Cell Type-Specific Access and Manipulation to Broaden Distribution of Enabling Technologies for Neuroscience (U24 Clinical Trial Not Allowed) | RFA-MH-21-180 | NIMH | This Funding Opportunity Announcement (FOA) from the NIH Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is intended to support establishment of facilities at… More | ||
| Notice of Change to Key Dates for PAR-21-263, "Computational Approaches for Validating Dimensional Constructs of Relevance to Psychopathology (R01 Clinical Trial Optional) | NOT-MH-22-180 | NIMH | This Notice modifies key dates for PAR-21-263 | ||
| Computationally-Defined Behaviors in Psychiatry (R21 Clinical Trial Optional) | PAR-21-264 | NIMH | Reissue of RFA-MH-19-240. This Funding Opportunity Announcement (FOA) solicits proposals for research projects that will apply computational approaches to develop parametrically detailed behavioral… More | ||
| Computational Approaches for Validating Dimensional Constructs of Relevance to Psychopathology (R01 Clinical Trial Optional) | PAR-21-263 | NIMH | Reissue of RFA-MH-19-242.This Funding Opportunity Announcement (FOA) solicits proposals for research projects that will use computational approaches to test the validity of dimensional constructs in… More | ||
| Discovery of Cell-based Chemical Probes for Novel Brain Targets (R21 Clinical Trial Not Allowed) | PAR-21-028 | NIMH | This Funding Opportunity Announcement (FOA) intends to support investigators who have interest and capability to join efforts for the discovery of cell-based chemical probes for novel brain targets.… More | ||
| Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed) | PAR-21-029 | NIMH | This Funding Opportunity Announcement (FOA) intends to support investigators who have interest and capability to join efforts for the discovery of in vivo chemical probes for novel brain targets. It… More | ||
| BRAIN Initiative Cell Atlas Network (BICAN): Specialized Collaboratory on Human, Non-human Primate, and Mouse Brain Cell Atlases (R01 Clinical Trial Not Allowed) | RFA-MH-22-292 | NIMH | This Funding Opportunity Announcement (FOA) intends to support a group of Specialized Collaboratories that will adopt scalable technology platforms and streamlined sampling strategies and assay… More | ||
| Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33 Clinical Trial Required) | PAR-21-134 | NIMH | This is a reissue of RFA-MH-18-705: Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33 Clinical Trial Required). As part of NIMH's clinical trials… More | ||
| Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required) | PAR-21-137 | NIMH | This is a reissue of RFA-MH-18-702: Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33- Clinical Trial Required). NIMH requires an… More | ||
| First in Human and Early Stage Clinical Trials of Novel Investigational Drugs or Devices for Psychiatric Disorders (U01 Clinical Trial Required) | PAR-21-133 | NIMH | The purpose of this Funding Opportunity Announcement (FOA) is to encourage cooperative agreement applications to support early stage clinical trials of novel mechanism of action, investigational… More | ||
| Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (Collaborative R01 Clinical Trial Required) | PAR-21-129 | NIMH | This is a reissue of RFA-MH-18-700: Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (Collaborative R01-- Clinical Trial Required). This FOA is a key… More | ||
| BRAIN Initiative: Brain Behavior Quantification and Synchronization (R61/R33 Clinical Trial Optional) | RFA-MH-23-335 | NIMH | The goal of this effort is to support the development and validation of next generation platforms and analytic approaches to precisely quantify behaviors in humans and link them with simultaneously… More | ||
| Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01 Clinical Trial Required) | PAR-21-130 | NIMH | This is a reissue of RFA-MH-18-701: Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01 Clinical Trial Required). This FOA is a key element of NIMHs… More | ||
| Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required) | PAR-21-136 | NIMH | This is a reissue of RFA-MH-18-703: Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required). NIMH requires an… More | ||
| Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders (R01 Clinical Trial Required) | PAR-21-132 | NIMH | This is a reissue of RFA-MH-18-707: Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders (R01 Clinical Trial Required). As part of NIMH's clinical… More | ||
| Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions (R34 Clinical Trial Required) | PAR-21-131 | NIMH | This is a reissue of RFA-MH-18-706: Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions (R34- Clinical Trial Required). As part of NIMH's clinical trials pipeline… More | ||
| Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33 Clinical Trial Required) | PAR-21-135 | NIMH | This is a reissue of RFA-MH-18-704: Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33 Clinical Trial Required). As part of NIMH's clinical trials… More | ||
| Research on Autism Spectrum Disorders (R01 Clinical Trial Optional) | PA-21-201 | NIMH | Reissue of the PA-18-401. The purpose of this Funding Opportunity Announcement (FOA) is to encourage research grant applications to support research designed to elucidate the etiology, epidemiology,… More | ||
| Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R01 Clinical Trial Required) | PAR-21-210 | NIMH | Reissue of PAR-18-430. NIMH seeks applications for research projects to evaluate the effectiveness of therapeutic and service delivery interventions for the post-acute management of mental health… More | ||
| Research on Autism Spectrum Disorders (R03 Clinical Trial Optional) | PA-21-199 | NIMH | Reissue of the PA-18-399. The purpose of this Funding Opportunity Announcement (FOA) is to encourage research grant applications to support research designed to elucidate the etiology, epidemiology,… More | ||
| Pilot Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R34 Clinical Trial Required) | PAR-21-211 | NIMH | Reissue of PAR-18-431. NIMH seeks applications for pilot effectiveness projects to evaluate the preliminary effectiveness of therapeutic and service delivery interventions for the post-acute… More | ||
| Research on Autism Spectrum Disorders (R21 Clinical Trial Optional) | PA-21-200 | NIMH | Reissue of the PA-18-400. The purpose of this Funding Opportunity Announcement (FOA) is to encourage research grant applications to support research designed to elucidate the etiology, epidemiology,… More | ||
| Mentored Career Transition Award for Intramural Fellows (K22 Clinical Trials Not Allowed) | PA-21-194 | NIMH | Reissue of PA-18-614. The Mentored Career Transition Award for NIMH Intramural Fellows (K22) is a two-phase, mentored career development award program that is intended to facilitate a timely… More | ||
| NIMH Exploratory/Developmental Research Grant (R21 Clinical Trial Not Allowed) | PA-21-235 | NIMH | Reissue of PA-18-350. The NIMH Exploratory/Developmental Grant program supports exploratory and high-risk research projects that fall within the NIMH mission by providing support for the early and… More | ||
| Mentored Career Transition Award for Intramural Fellows (K22 Clinical Trials Required) | PA-21-195 | NIMH | Reissue of PA-18-613. The Mentored Career Transition Award for NIMH Intramural Fellows (K22) is a two-phase, mentored career development award program that is intended to facilitate a timely… More | ||
| Understanding and Modifying Temporal Dynamics of Coordinated Neural Activity (R21 Clinical Trial Optional) | PAR-21-176 | NIMH | This R21 funding opportunity encourages projects that test, in animals and/or humans, whether modifying electrophysiological patterns can improve cognitive, affective, or social processing. This R21… More | ||
| Understanding and Modifying Temporal Dynamics of Coordinated Neural Activity (R01 Clinical Trial Optional) | PAR-21-175 | NIMH | This R01 funding opportunity encourages projects that test, in animals and/or humans, whether modifying electrophysiological patterns can improve cognitive, affective, or social processing. This R01… More | ||
| BRAIN Initiative: Integration and Analysis of BRAIN Initiative Data (R01 Clinical Trial Not Allowed) | RFA-MH-22-220 | NIMH | This is a reissue of RFA-MH-21-135. This FOA supports the development of software to visualize and analyze the data as part of programs of building the informatics infrastructure for the BRAIN… More | ||
| BRAIN Initiative: Development of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in Human and Non-Human Primate Brain (UG3/UH3 Clinical Trial Optional) | RFA-MH-22-115 | NIMH | Reissue of RFA-MH-19-135 The purpose of this Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is to encourage applications that will develop and validate novel tools… More | ||
| BRAIN Initiative: Standards to Define Experiments Related to the BRAIN Initiative (R01 Clinical Trial Not Allowed) | RFA-MH-22-145 | NIMH | Reissue of RFA-MH-20-128 This Funding Opportunity Announcement (FOA) solicits applications to develop standards that describe experimental protocols that are being conducted as part of the BRAIN… More | ||
| Innovative Mental Health Services Research Not Involving Clinical Trials (R01 Clinical Trials Not Allowed) | PAR-23-095 | NIMH | The purpose of this funding announcement is to encourage innovative research that will inform and support the delivery of high-quality, continuously improving mental health services to benefit the… More | ||
| Effectiveness of Implementing Sustainable Evidence-Based Mental Health Practices in Low-Resource Settings to Achieve Mental Health Equity for Traditionally Underserved Populations (R01 Clinical Trial Optional) | PAR-23-092 | NIMH | This Funding Opportunity Announcement (FOA) encourages studies that develop and test the effectiveness of strategies for implementation and sustainable delivery of evidence-based mental health… More | ||
| Initiation of a Mental Health Family Navigator Model to Promote Early Access, Engagement and Coordination of Needed Mental Health Services for Children and Adolescents (R01 Clinical Trial Required) | PAR-23-094 | NIMH | The purpose of this Funding Opportunity Announcement (FOA) is to encourage research applications to develop and test the effectiveness and implementation of family navigator models designed to… More | ||
| Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R01 Clinical Trial Optional) | PAR-23-093 | NIMH | The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to pursue invasive neural recording studies focused on mental health-relevant questions. Invasive neural… More | ||
| Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R21 Clinical Trial Optional) | PAR-23-101 | NIMH | Reissue of RFA-20-351.The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to pursue invasive neural recording studies focused on mental health-relevant questions.… More | ||
| NIMH Research Education Mentoring Program for HIV/AIDS Researchers (R25 Clinical Trial Not Allowed) | PAR-21-228 | NIMH | Reissue of PAR-17-485. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this National Institute of Mental… More | ||
| Pilot Studies to Test the Initiation of a Mental Health Family Navigator Model to Promote Early Access, Engagement and Coordination of Needed Mental Health Services for Children and Adolescents (R34 Clinical Trial Required) | PAR-23-104 | NIMH | The purpose of this Funding Opportunity Announcement (FOA) is to encourage research applications to develop and pilot test the effectiveness and implementation of family navigator models designed to… More | ||
| NIMH Career Transition Award for Tenure-Track Intramural Investigators (K22 No Independent Clinical Trials) | PAR-21-239 | NIMH | Reissue of PAR-18-755. The primary goal of the NIMH Career Transition Award for Tenure-Track Intramural Investigators (K22) Program (hereafter abbreviated as the NIMH Career Transition K22 Program)… More | ||
| Implementing and Sustaining Evidence-Based Mental Health Practices in Low-Resource Settings to Achieve Equity in Outcomes (R34 Clinical Trial Required ) | PAR-23-103 | NIMH | Reissue of RFA-MH-20-401.This Funding Opportunity Announcement (FOA) supports pilot work for subsequent studies testing the effectiveness of strategies to deliver evidence-based mental health… More | ||
| NIMH Instrumentation Program (S10 Clinical Trial Not Allowed) | RFA-MH-22-155 | NIMH | Reissue of RFA-MH-20-555. The NIMH Instrumentation Program encourages applications from NIH funded investigators to purchase or upgrade a single commercially available instrument or a group of… More | ||
| BRAIN Initiative: Engineering and optimization of molecular technologies for functional dissection of neural circuits (UM1 Clinical Trial Not Allowed) | RFA-MH-22-245 | NIMH | This BRAIN Initiative FOA is to further develop molecular tools of high impact that are targetable to brain cell types for the monitoring and manipulation of neural circuits in experimental animals… More | ||
| Mood and Psychosis Symptoms during the Menopause Transition (R01 Clinical Trial Optional) | PAR-23-097 | NIMH | The purpose of this FOA is to advance translational research to better understand the emergence and worsening of mood and psychotic disorders (e.g., perimenopausal depression (PMD), generalized… More | ||
| Drug Discovery For Nervous System Disorders (R01 Clinical Trials Not Allowed) | PAR-22-031 | NIMH | Reissue of PAR-19-147 This Funding Opportunity Announcement (FOA) supports the discovery of novel compounds for the prevention and treatment of nervous system disorders. Through this FOA NIMH… More |
||
| Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional) | PAR-23-102 | NIMH | Reissue of RFA-MH-21-106 The purpose of this FOA is to advance translational research to better understand the emergence and worsening of mood and psychotic disorders (e.g., perimenopausal depression… More | ||
| Basic Neurodevelopmental Biology of Circuits and Behavior (R01 Clinical Trial Not Allowed) | PAR-22-066 | NIMH | Reissue of PAR-19-027 This Funding Opportunity Announcement (FOA) solicits research projects focused on the dynamic and mechanistic links between the maturation of brain circuits and behaviors across… More | ||
| Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R21 Clinical Trial Not Allowed) | PAR-22-038 | NIMH | Reissue of PAR-18-941. The purpose of this funding opportunity announcement (FOA) is to encourage applications seeking to develop the next generation of brain stimulation devices for treating mental… More | ||
| Drug Discovery For Nervous System Disorders (R21 Clinical Trials Not Allowed) | PAR-22-032 | NIMH | Reissue of PAR-19-146 This Funding Opportunity Announcement (FOA) supports the discovery of novel compounds for the prevention and treatment of nervous system disorders. Through this FOA NIMH… More |
||
| Neuromodulation/ |